



E. A. Davis Company

Always at your side...

# IV Therapy Notes

**Nurse's Clinical Pocket Guide**

Lynn D. Phillips

**Waterproof  
and  
Reusable**

Includes...

- ✓ **Wipe-Free Forms**
- ✓ **Administering IV Meds**
- ✓ **IV Piggyback Setup**
- ✓ **IV Compatibilities with Potassium**
- ✓ **Flushing IV Catheters**
- ✓ **Starting IVs**
- ✓ **Essentials of Fluid & Electrolytes**
- ✓ **Calculating IV Fluid Rates**
- ✓ **Nutritional Assessment**
- ✓ **Peripheral and Central Lines**

and more!

## Contacts • Phone/E-Mail

Name

Ph: e-mail:

Name

Ph: e-mail:

Name

Ph: e-mail:

Name

Ph: e-mail:

Name

Ph: e-mail:

Name

Ph: e-mail:

Name

Ph: e-mail:

Name

Ph: e-mail:

Name

Ph: e-mail:

Name

Ph: e-mail:

Name

Ph: e-mail:

Name

Ph: e-mail:

# IV Therapy Notes

Nurse's Pharmacology Pocket Guide

Lynn D. Phillips

Purchase additional copies of this book at your health science bookstore or directly from F. A. Davis by shopping online at [www.fadavis.com](http://www.fadavis.com) or by calling 800-323-3555 (US) or 800-665-1148 (CAN)

A Davis's Notes Book



F. A. Davis Company • Philadelphia

F. A. Davis Company  
1915 Arch Street  
Philadelphia, PA 19103  
www.fadavis.com

Copyright © 2005 by F. A. Davis Company

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher.

Printed in China by Imago

Last digit indicates print number: 10 9 8 7 6 5 4 3 2 1

*Publisher, Nursing:* Joanne Patzek DaCunha, RN, MSN

*Project Editor:* Ilysa H. Richman

*Design Manager:* Joan Wendt

As new scientific information becomes available through basic and clinical research, recommended treatments and drug therapies undergo changes. The author(s) and publisher have done everything possible to make this book accurate, up to date, and in accord with accepted standards at the time of publication. The author(s), editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of the book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised always to check product information (package inserts) for changes and new information regarding dose and contraindications before administering any drug. Caution is especially urged when using new or infrequently ordered drugs.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by F. A. Davis Company for users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the fee of \$.10 per copy is paid directly to CCC, 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is: 8036-1288-5/05 0 1 \$.10.

Place  $2\frac{7}{8} \times 2\frac{7}{8}$  **Sticky Notes** here  
for a convenient and refillable note pad

- ✓ HIPAA Compliant
- ✓ OSHA Compliant

**Waterproof and Reusable  
Wipe-Free Pages**

**Write directly onto any page of *IV Therapy Notes* with a ballpoint pen. Wipe old entries off with an alcohol pad and reuse.**

Basics

F & E

Periph

Central

Blood

Nutri  
Support

Med  
Admin

Tools

## Look for our other Davis's Notes titles

### Available Now!

**RNotes™:** *Nurse's Clinical Pocket Guide*  
ISBN: 0-8036-1060-2

**LPN Notes:** *Nurse's Clinical Pocket Guide*  
ISBN: 0-8036-1132-3

**MedNotes:** *Nurse's Pocket Pharmacology Guide*  
ISBN: 0-8036-1109-9

**MedSurg Notes:** *Nurse's Clinical Pocket Guide*  
ISBN: 0-8036-1115-3

**NutriNotes:** *Nutrition and Diet Therapy Pocket Guide*  
ISBN: 0-8036-1114-5

### Coming Soon

**LabNotes:** *Guide to Lab & Diagnostic Tests*  
ISBN: 0-8036-1265-6

**PsychNotes:** *Clinical Pocket Guide*  
ISBN: 0-8036-1265-6

**ECG Notes:** *Interpretation and Management Pocket Guide*  
ISBN: 0-8036-1265-6

**OrthoNotes:** *A Clinical Examination Pocket Guide*  
ISBN: 0-8036-1350-4

**MA Notes:** *Medical Assistant's Pocket Guide*  
ISBN: 0-8036-1281-8

### Also by Lynn Diane Phillips

*Manual of I.V. Therapeutics, 4<sup>th</sup> Edition*  
ISBN: 0-8036-1187-0

**Contents: BASICS**

Common Formulas	2
Body Surface Area (BSA)	2
Pediatric Formulas	3
Pediatric IV Solutions	3
Universal Formula for Calculating Drip Rates and Drug Amounts	5
IV Fluid Rates in Drops per Minute	6
Basic Formula	7
General Dilution Chart (G to mg)	8
General Dilution Chart (mg to $\mu\text{g}$ )	9

## Common Formulas

**Syringe**  
(Amount to  
be drawn up)

$$\times (\text{Drug}) = \frac{\text{Desired amount} \times \text{Total volume}}{\text{Total amount of drug on hand}}$$

**mL/hr**—  
Infusion rate

$$\times \frac{\text{drops}}{\text{min}} = \frac{\text{Desired amount} \times \text{drop factor of tubing}}{\text{Time in minutes}}$$

Programming  
Pump  
Units/Hour

$$\frac{D \times Q \text{ Method}}{A} \times \text{mL} = \frac{\text{Desired} \times \text{mL of fluid}}{\text{Available}}$$

Micrograms/  
Kilogram/  
Minute

$$\times \text{mL/h} = \text{Ordered } \mu\text{g/min} \times \text{pt.}$$

$$\frac{\text{Weight in kg} \times 60 \text{ min/1 hr}}{\text{Medication concentration (No. of } \mu\text{g/mL)}}$$

**To calculate volume/hour**

$$\text{Total Volume} \div \text{Administration time} = \text{mL (volume)/hour}$$

**To calculate drops/minute**

$$\times \text{gtt/min} = \frac{\text{Hourly Volume} \times \text{gtt factor of tubing}}{\text{Time in minutes (60)}}$$

(i.e. 125 mL) (i.e. 15 gtt/mL drop factor)

**Body Surface Area (BSA)**

Using cm  
& kg:  $\sqrt{\frac{\text{Ht (cm)} \times \text{Wt (kg)}}{3600}}$

Using inches  
& lb:  $\sqrt{\frac{\text{Ht (in)} \times \text{Wt (lbs)}}{3131}}$



## Pediatric Formulas

### Key Points

- Child's weight in kilograms
- What is the safe recommended dosage or range?
- Is the order safe?
- How many milligrams will you administer?

### Milligram/kilogram/hour

$$X \text{ mL} = \text{mg} \times \text{kg wt} \times 24 \text{ hours}$$

### Body Surface Area (BSA)

#### Dose based on BSA (use West nomogram)

$$\frac{\text{BSA in m}^2 \times \text{Recommended adult dose}}{\text{BSA of adult (1.7)}} = \text{Child dose}$$

Clark's Rule:

Dose based on child's weight

$$\frac{\text{Weight (lb)} \times \text{Average adult dose}}{\text{Average adult weight}} = \frac{\text{Child dose}}{150 \text{ lbs}}$$

## Pediatric IV Solutions

### Key Points

- Pediatric formulas are not different from those of adults; however, the difference is the amount of volume of solution used.
- Pediatric patients require a smaller volume of IV solutions.
- Accurate calculation of drug to volume of solution is important to prevent vein irritation.

### Pediatric IV Medications by Pump

$$X \text{ mL/hour} = \frac{\text{Total volume to be infused (in mL)}}{\text{Total amount of time for infusion (in hours)}}$$

### If to be infused by Volume Control Set by gravity

$$X \text{ gtt/min} = \frac{\text{Total volume to be infused (in mL)} \times \text{gtt factor}}{\text{Total amount of time for infused (in minutes)}}$$

Example: An 18-month-old child has Ancef 450 mg q 4 h IVPB over 15 minutes. The child weighs 19 kg. The maximum recommended infusion concentration is 50 mg/mL. The vial is Ancef 250 mg/mL. How many mL of medication will be provided in 450 mg? How many mL of IV solution needs to be added to equal the recommended final concentration? What should the IV pump be programmed for?

- Calculate volume of medication to be withdrawn from vial  
250 mg: 1 mL :: 450 : X mL  
 $250 \times = 450$

$$X = \frac{450}{250}$$

$$X = 1.8 \text{ mL}$$

- Calculate the volume of IV solution

$$\frac{\text{Ordered dose} \times 1 \text{ mL}}{\text{Recommended concentration}} = X \text{ mL}$$

$$\frac{450 \text{ mg} \times 1 \text{ mL}}{50 \text{ mg}} = 9 \text{ mL}$$

Therefore: to the 1.8 mL of Ancef, the nurse must add enough IV solution to give a TOTAL of 9 mL

$$9 \text{ mL} - 1.8 \text{ mL} = 7.2 \text{ mL}$$

Add 7.2 mL of compatible IV fluid to volume control chamber, then add 1.8 mL of Ancef to make a total volume of 9 mL

Final concentration: 50 mg/mL

- Calculate the mL/h to program the pump

$$\frac{9 \text{ mL}}{0.25 \text{ hr}} = \mathbf{36 \text{ mL/hr}}$$


## Universal Formula for Calculating Drip Rates and Drug Amounts

This is a universal formula and will work in most cases, whether a certain amount of drug needs to be drawn up in a syringe, given over a certain amount of time via IV infusion, or given as a maintenance IV (mL/hr), etc.

**1a** Enter the amount of drug that is ordered.  mg, g, µg, etc. ( )

Enter weight in kg if applicable; otherwise, leave blank.  kg

For mL/hr only (no drugs), use the boxes highlighted in yellow [(Vol x gtt)/Time]. **Volume** mL

IV Push Orders  Follow step 1 to find volume to be drawn up in a syringe.

**2** Multiply step 1 by drip (gtt) factor. **Drip Factor** (gtt/mL)

**1b** When medication is part of the equation, enter the total amount of drug you have on hand here.  mg, g, µg, etc. ( )

**1c** Then enter the total volume on hand here.

**Legend**  
 mL/hr = [(Vol x gtt)/time]  
 mg/min = steps 1a-c, 2, 3  
 mg/kg/min = fill every box  
 Syringe = steps 1a-c

To figure out the running time (mL/hr) on an existing IV, first count the drops per minute. Then multiply that amount by 60 and divide the result by the drip factor being used.

**3** **Time** minutes =  gtt/min

Divide the results obtained in steps 1 and 2 by the number of minutes over which the medication or fluid has been ordered.

## IV Fluid Rates in Drops per Minute

Order— mL/hr	10 Drops/ mL	15 Drops/ mL	20 Drops/ mL	60 Drops/ mL
10	2	3	3	10
15	3	4	5	15
20	3	5	7	20
30	5	8	10	30
50	8	13	17	50
75	13	19	25	N/A
80	13	20	27	N/A
100	17	25	33	N/A
120	20	30	40	N/A
125	21	31	42	N/A
150	25	38	50	N/A
166	27	42	55	N/A
175	29	44	58	N/A
200	33	50	67	N/A
250	42	63	83	N/A
300	50	75	100	N/A

**Note:** Microdrip tubing is not appropriate for rates over 50 mL/hr.

## Basic Formula

$$X \text{ gtt/min} = \frac{\text{mL per hour} \times \text{Drop factor minute}}{60 \text{ minutes}}$$

Use this page to calculate your drop rates (gtt/hour) for gravity infusions

$$\text{Drip rate} = \frac{(\text{Hourly volume})}{(\text{Time})} \times (\text{Drop factor tubing})$$

$$\text{Drip rate} = \frac{(\text{Hourly volume})}{(\text{Time})} \times (\text{Drop factor tubing})$$

$$\text{Drip rate} = \frac{(\text{Hourly volume})}{(\text{Time})} \times (\text{Drop factor tubing})$$

$$\text{Drip rate} = \frac{(\text{Hourly volume})}{(\text{Time})} \times (\text{Drop factor tubing})$$

$$\text{Drip rate} = \frac{(\text{Hourly volume})}{(\text{Time})} \times (\text{Drop factor tubing})$$

**Note:** When using an EID that is mL/hr, the drip rate is the same as for 60 gtt tubing (hourly volume = drip rate); e.g., 75 mL/hr would be 75 mL/hr.

## General Dilution Chart (g to mg)

### Amount of Diluent

#### Amount of Drug in Grams

Grams	1000 mL	500 mL	250 mL	125 mL	100 mL	50 mL	25 mL
	mg/mL	mg/mL	mg/mL	mg/mL	mg/mL	mg/mL	mg/mL
0.25	0.25	0.5	1	2	2.5	5	10
0.5	0.5	1	2	4	5	10	20
1	1	2	4	8	10	20	40
1.5	1.5	3	6	12	15	30	60
2	2	4	8	16	20	40	80
2.5	2.5	5	10	20	25	50	100
3	3	6	12	24	30	60	120
3.5	3.5	7	14	28	35	70	140
4	4	8	16	32	40	80	160
4.5	4.5	9	18	36	45	90	180
5	5	10	20	40	50	100	200
6	6	12	24	48	60	120	240
7	7	14	28	56	70	140	280
8	8	16	32	64	80	160	320
9	9	18	36	72	90	180	360
10	10	20	40	80	100	200	400

#### To Use Chart

- Find mg/mL desired; track to amount of diluent desired and amount of drug in g required.
- Find amount of drug in g required; track to diluent desired and/or mg/mL desired.
- Find amount of diluent required; track to amount of drug in g and/or mg/mL desired.

#### Formula:

X g diluted in X amount = X mg/mL (Example: 1 g in 1000 mL = 1 mg/mL)

## General Dilution Chart (mg to $\mu\text{g}$ )

### Amount of Diluent

Amount of Drug in mg	Amount of Diluent						
	1000 mL	500 mL	250 mL	125 mL	100 mL	50 mL	25 mL
Milligrams	$\mu\text{g/mL}$	$\mu\text{g/mL}$	$\mu\text{g/mL}$	$\mu\text{g/mL}$	$\mu\text{g/mL}$	$\mu\text{g/mL}$	$\mu\text{g/mL}$
0.25	0.25	0.5	1	2	2.5	5	10
0.5	0.5	1	2	4	5	10	20
1	1	2	4	8	10	20	40
1.5	1.5	3	6	12	15	30	60
2	2	4	8	16	20	40	80
2.5	2.5	5	10	20	25	50	100
3	3	6	12	24	30	60	120
3.5	3.5	7	14	28	35	70	140
4	4	8	16	32	40	80	160
4.5	45	9	18	36	45	90	180
5	5	10	20	40	50	100	200
6	6	12	24	48	60	120	240
7	7	14	28	56	70	140	280
8	8	16	32	64	80	160	320
9	9	18	36	72	90	180	360
10	10	20	40	80	100	200	400

### To Use Chart

- Find  $\mu\text{g/mL}$  desired, track to amount of diluent desired and amount of drug in mg required.
- Find amount of drug in mg required; track to diluent desired and/or  $\mu\text{g/mL}$  desired.
- Find amount of diluent required; track to amount of drug in mg and/or  $\mu\text{g/mL}$  desired.

### Formula:

X mg diluted in X mL of solution = X  $\mu\text{g/mL}$  (1 mg in 1000 mL = 1  $\mu\text{g/mL}$ )

## Notes



**Contents: F & E**

Percentage of Total Body Fluid in Relation to Age and Gender	12
Osmolarity of Fluids	12
Effects of Fluid Shifts in Isotonic, Hypotonic, and Hypertonic States	13
Fluid Imbalances	14
Sodium Imbalances	15
Potassium Imbalances	16
Critical Guidelines for Administration of Potassium	17
IV Potassium Compatibilities	18
Calcium Imbalance	21
Magnesium Imbalance	23
Chloride Imbalance	24
Acid-Base Scale	24
The Body's Reaction to Acid-Base Imbalance	25
Common Causes of Acid-Base Imbalance	25
Summary of Acute Acid-Base Imbalances	26
Parenteral Solutions - Fast Facts	27
Colloid Solutions	28
Intravenous Solutions Chart	29

## Percentage of Total Body Fluid in Relation to Age and Gender

Age	% of Water = Body Weight
Full-term newborn	70 to 80
Infant to 1 year	64
Puberty to 39 years	Men: 60 Women: 55
40–60 years	Men: 55 Women: 47
Over 60 years	Men: 52 Women: 46


## Osmolarity of Fluids

Normal body fluids	280–295 mOsm/L
Isotonic fluids	250–375 mOsm/L
Hypotonic fluids	Below 250 mOsm/L
Hypertonic fluids	Above 375 mOsm/L

## Effects of Fluid Shifts in Isotonic, Hypotonic, and Hypertonic States


### HYPOTONIC

Less than body less 250 mEq/kg




### ISOTONIC

Equal to body 290 mEq/kg



### HYPERTONIC

More than body greater 375 mEq/kg



## Fluid Imbalances

**Sodium: Normal value 135–145 mEq/L**

	<b>Cause</b>	<b>Signs/Symptoms</b>	<b>Treatment</b>
<i>Fluid Volume Deficit</i>	Acute weight loss, changes in mental status, posture, hypotension, dizziness, syncope, vertigo, distention of neck vein, decreased central venous pressure, weak pulse, nausea, vomiting and anorexia, increased thirst, decreased urine output, poor skin turgor over sternum and forehead, dry skin and mucous membrane, sunken eyes	<p><b>Serum</b>                      Hematocrit: Increased                      Hemoglobin: Increased                      Proteins: Increased                      Osmolarity: Normal</p> <p><b>Urine</b>                      Sodium: &lt;50 mEq/L                      Osmolarity: &gt;500 mOsm/L                      Specific gravity: Above 1.030</p>	Restore fluid and electrolyte balance using isotonic sodium chloride solutions. Treat underlying cause.
<i>Fluid Volume Excess</i>	Weight gain; edema occurs when 2–4 kg of fluid is retained; altered respiratory and cardiovascular function: hypertension, tachycardia; altered LOC, skeletal muscle weakness, and increased bowel sounds	<p><b>Serum</b>                      Hematocrit: Normal to low                      Hemoglobin: Normal to low                      Proteins: Normal to low                      Osmolarity: Normal                      BUN: Normal to low</p> <p><b>Urine</b>                      Sodium: Reduced                      Osmolarity &lt;500 mOsm/L                      Specific gravity: 1.010</p>	Reduce fluid retention by salt and fluid restriction. Diuretics to increase fluid excretion. Treat underlying cause.

## Sodium Imbalances

**Sodium: Normal value 135–145 mEq/L**

	Cause	Signs/Symptoms	Treatment
<p><i>Sodium Deficit</i> <i>Hyponatremia</i> <i>Serum Na<sup>+</sup></i> <i>&lt; 135</i></p>	<p>Abnormal loss of GI secretions (vomiting, diarrhea); losses from skin; hormonal—SIADH Oxytocin Adrenal insufficiency</p>	<p>Na<sup>+</sup> &lt; 115: affects CNS cells Headache Sensation of taste impaired Anorexia Feeling exhausted, muscle cramps Focal weakness (hemiparesis, ataxia)</p>	<p>Replace sodium and fluid losses. Restore normal ECF volume. Correct any other electrolyte losses.</p>
<p><i>Sodium Excess</i> <i>Hypernatremia</i> <i>Serum Na<sup>+</sup> &gt; 145</i></p>	<p>Person who cannot respond to thirst Hypertonic tube feeding Administration of sodium-containing solutions Drowning in seawater Heat stroke</p>	<p>Marked thirst Temperature Swollen tongue Red, dry, sticky membranes Disorientation Irritability Hyperactivity</p>	<p>Infuse hypotonic saline solution or 5%D/W Use diuretics</p>

## Potassium Imbalances

Normal value 3.5–5.5 mEq/L

	Cause	Signs/Symptoms	Treatment
<p><i>Potassium Deficit</i> <i>Hypokalemia</i> <i>Serum K<sup>+</sup> &lt;3.5</i></p>	<p>Prolonged gastric losses Laxative overuse Potassium-wasting diuretic therapy Drugs such as sodium penicillin, carbenicillin, glucocorticoids Sweat losses</p>	<p>Neuromuscular changes Fatigue, muscle weakness, diminished deep tendon reflexes Anorexia, nausea ECG changes Increased sensitivity to digitalis</p>	<p>Mild: Dietary potassium supplements Potassium replacement by IV (See guidelines for administration of potassium)</p>
<p><i>Potassium Excess</i> <i>Hyperkalemia</i> <i>Serum K<sup>+</sup> &gt;5.5</i></p>	<p>Increase in potassium intake, oral or IV Decreased urinary excretion of potassium Shift of K<sup>+</sup> out of cells</p>	<p>Changes to ECG Vague muscle weakness Anxiety, nausea, cramping, diarrhea</p>	<p>Restrict dietary K<sup>+</sup> Administer regular insulin (10–25 U) in hypertonic dextrose to shift K<sup>+</sup> Sodium polystyrene sulfonate Peritoneal dialysis</p>

## Critical Guidelines for Administration of Potassium

- **NEVER give potassium IV push (FATAL).**
- Do not give more than 120 mEq/24 hours without ICU monitoring.
- Potassium chloride (KCl) is compatible with most IV solutions.
- Never administer concentrated potassium without first diluting.
- Potassium solutions in commonly used strengths (20 or 40 mEq/L) are available in premixed form from manufacturers.
- KCl preparations greater than 60 mEq/L **should not** be given in peripheral vein.
- Make sure KCl mixes with the solution thoroughly—invert and agitate the container to ensure mixing.
- Do not add KCl to a hanging container!
- Administer potassium at a rate not to exceed 10 to 20 mEq/hr.
- For extreme hypokalemia, rates should be no more than 40 mEq/h while ECG is monitored.
- KCl administered into the subcutaneous tissue (infiltrated) is extremely irritating and can cause tissue damage. Use extravasation protocol.
- Use infusion pump to control flow rate.
- Use extreme caution for hourly replacement of potassium by secondary infusion.
- Potassium is primarily excreted through the kidneys—check kidney function!

## IV Potassium Compatibilities

### Medications Compatible with IV Potassium Chloride

acyclovir	droperidol/fentanyl
alatrovafloxacin	edrophonium
aldesleukin	enalaprilat
allopurinol	epinephrine
amifostine	esmolol
aminophylline	conjugated estrogens
amiodarone	ethacrynate sodium
ampicillin	etoposide
amrinone	famotidine
atropine	fentanyl
aztreonam	filgrastim
betamethasone	fludarabine
calcium gluconate	fluorouracil
chlordiazepoxide	furosemide
chlorpromazine	gatifloxacin
cimetidine	gemcitabine
ciprofloxacin	granisetron
cisatracurium	heparin
cladribine	hydralazine
cyanocobalamin	idarubicin potassium
dexamethasone	indomethacin
digoxin	insulin
diltiazem	isoproterenol
diphenhydramine	kanamycin
dobutamine	labetalol
docetaxel	lidocaine
dopamine	linezolid
doxorubicin liposome	lorazepam
droperidol	magnesium sulfate




**Medications Compatible with IV Potassium Chloride (Cont'd)**


melphalan	propofol
menadiol	propranolol
meperidine	pyridostigmine
methoxamine	ranitidine
methylergonovine	remifentanyl
midazolam	sargramostim
minocycline	scopolamine
morphine	sodium bicarbonate
neostigmine	succinylcholine
norepinephrine	tacrolimus
ondansetron	teniposide
oxacillin	theophylline
oxytocin	thiotepa
paclitaxel	tirofiban
penicillin G potassium	trimethaphan
pentazocine	trimethobenzamide
phytonadione	vinorelbine
piperacillin/tazobactam	warfarin
procainamide	zidovudine
prochlorperazine edisylate	

**Medications Incompatible with IV Potassium**

adrenaline HCl	ergotamine tartrate
amphotericin B cholesteryl sulfate complex	methicillin sodium
atropine sulphate	phenytoin
cephalothin sodium	phenytoin sodium
chloramphenicol sodium succinate	sulphadiazine sodium
chlorpromazine HCl	suxamethonium chloride
diazepam	thiopentone sodium



**Hypokalemia**—ECG tracing has ST-segment depression, flattened T-wave, and a U-wave.



**Hyperkalemia**—ECG tracing has tall, thin T-waves; prolonged PR intervals; ST-segment depression; widened QRS; loss of P-wave.

## Calcium Imbalance

	Cause	Signs/Symptoms	Treatment
<p><i>Calcium Deficit</i> <i>Hypocalcemia</i> <i>Serum level</i> <i>&lt;8.5 mg/dL</i></p>	<p>Inadequate secretion of PTH caused by primary hypoparathyroidism or surgically induced hypoparathyroidism; also results from calcium loss through diarrhea, wound exudate, acute pancreatitis, hyperphosphatemia associated with renal failure. Prolonged NG suctioning. Infusion of citrated blood.</p>	<p>Neuromuscular symptoms (numbness of fingers, cramps in muscles), hyperactive deep tendon reflexes, and positive Trousseau's sign and Chvostek's sign. Irritability, memory impairment, delusions, seizures (late), prolonged QT interval, and altered CV hemodynamics. Laryngospasms and tetany-like contractions.</p>	<p>Alleviate underlying cause. Administration of calcium gluconate (orally or IV). IV 10–20 mL of a 10% solution in 5% D/W for 20 minutes.</p>
<p><i>Calcium Excess</i> <i>Hypercalcemia</i> <i>Serum calcium</i> <i>&gt;10.5</i> <i>Symptoms occur when</i> <i>12 mg/dL or higher</i></p>	<p>Excessive release of calcium from bone. Hyperparathyroidism, multiple fractures, overuse of calcium-containing antacids. Patients with solid tumors that have metastasized or hematologic tumors. Drugs that can increase calcium levels include mega-doses of vitamins A or D, diuretics, androgens, estrogens, IV lipids, lithium, and tamoxifen.</p>	<p>Neuromuscular symptoms such as muscle weakness, incoordination, lethargy, deep bone pain, flank pain, pathologic fractures. Constipation, anorexia, nausea, vomiting, polyuria, and renal colic. Patients taking digitalis must take calcium with extreme caution.</p>	<p>Administer calcitonin. Occasionally, plicamycin administered, which inhibits bone reabsorption and lowers serum calcium.</p>

**Positive Trousseau's Sign**

Carpopedal attitude of the hand when blood pressure cuff is placed on the arm and inflated above systolic pressure for 3 minutes. Positive reaction is the development of carpal spasm.

**Positive Chvostek's Sign**

Occurs after tapping the facial nerve approximately 2 cm anterior to the earlobe.

## Magnesium Imbalance


**Normal Value: 1.5 to 2.5 mEq/L**

	<b>Cause</b>	<b>Signs/Symptoms</b>	<b>Treatment</b>
<p><i>Magnesium Deficit</i>  <i>Hypomagnesemia</i>  <i>Serum value</i>  <i>&lt;1.0 mEq/L</i></p>	<p>Chronic alcoholism; malabsorption syndrome, prolonged malnutrition or starvation; prolonged diarrhea; acute pancreatitis, prolonged NG suctioning.                      Administration of magnesium-free IV solutions past 1 week.</p>	<p>Neuromuscular symptoms, hyperactive reflexes, coarse tremors, muscle cramps, positive Chvostek's and Trousseau's signs, seizures, paresthesia of feet and legs, painfully cold hands and feet, disorientation, tachycardia, and increased potential for digitalis toxicity</p>	<p>Administer oral magnesium salts.                      Administer 40 mEq (5 g) magnesium sulfate added to 1 L of 5% D/W.                      Administer 1 to 2 g of 10% solution of magnesium sulfate by direct IV push at rate of 1.5 mL/min.</p>
<p><i>Magnesium Excess</i>  <i>Hypermagnesemia</i>  <i>Serum value</i>  <i>&gt;2.5 mEq/L</i></p>	<p>Renal failure                      Hyperparathyroidism; hyperthyroidism; excessive magnesium administration during treatment of patients with eclampsia.</p>	<p>Neuromuscular symptoms such as flushing and sense of skin warmth, lethargy, sedation, hypoactive deep tendon reflexes, depressed respirations, and weak or absent cry in newborn.                      Hypotension, sinus bradycardia, heart block, cardiac arrest (&gt;15 mEq/L), nausea, vomiting, and seizures</p>	<p>Administer calcium gluconate to antagonize the action of magnesium.                      Support respiratory function.                      Peritoneal or hemodialysis.</p>

## Chloride Imbalance

	Cause	Signs/ Symptoms	Treatment
<i>Chloride Deficit Hypochloremia Serum Chloride &gt;95 mEq/L</i>	GI losses Acute infection and use of chlorothiazide diuretics  <b>Note:</b> Serious acid-base imbalances occur with chloride imbalances	Neuromuscular symptoms such as tetany and hypertonic reflexes.  Depressed respirations and excessive loss of chlorides result in alkalosis  Increase in $\text{HCO}_3^-$ levels	Treat underlying cause (alkalosis) Administer sodium chloride solutions

## Acid-Base Scale



### The Body's Reaction to Acid-Base Imbalance

Condition	pH	Paco <sub>2</sub>	HCO <sub>3</sub>	How the Body Compensates
<b>Respiratory acidosis</b>	↓	↑ or normal	↑	Kidneys conserve HCO <sub>3</sub> and eliminate H <sup>+</sup> to increase pH
With compensation	Slightly ↓ or normal	↑	↑	
<b>Respiratory alkalosis</b>	↑	↓ or normal	↓	Kidneys eliminate HCO <sub>3</sub> and conserve H <sup>+</sup> to decrease pH
With compensation	Slightly ↓ or normal	↓	↓	
<b>Metabolic acidosis</b>	↓	↓	↓ or normal	Hyperventilation to blow off excess CO <sub>2</sub> and conserve HCO <sub>3</sub>
With compensation	Slightly ↓ or normal	↓	↓	
<b>Metabolic alkalosis</b>	↑	↑	↑ or normal	Hypoventilation to ↑ CO <sub>2</sub> ; kidneys keep H <sup>+</sup> and excrete HCO <sub>3</sub>
With compensation	Slightly ↓ or normal	↑	↑	

### Common Causes of Acid-Base Imbalance

Respiratory acidosis	Asphyxia, respiratory depression, CNS depression
Respiratory alkalosis	Hyperventilation, anxiety, PE (causing hyperventilation)
Metabolic acidosis	Diarrhea, renal failure, salicylate overdose such as ASA (aspirin)
Metabolic alkalosis	Hypercalcemia, overdose on an alkaline substance such as antacid

## Summary of Acute Acid-Base Imbalances

Acid-Base Imbalance	pH	Paco <sub>2</sub>	HCO <sub>3</sub>	Signs & Symptoms	Causes
<i>Acute Metabolic Acidosis</i>	↓	N* *↓	↓*	Tachypnea; Kussmaul's respirations; hypotension; cold, clammy skin; coma; dysrhythmias	Shock, arrest, ketoacidosis, starvation, acute renal failure, ingestion of acids
<i>Metabolic Alkalosis</i>	↑	N *↑	↑*	Muscular weakness, hyporeflexia, dysrhythmias, apathy, confusion	Volume depletion, gastric drainage, vomiting, diuretic use, aldosteronism, severe potassium depletion
<i>Respiratory Acidosis</i>	↓	↑	No change ↑*	Tachycardia, tachypnea, diaphoresis, headache, restlessness, coma, cyanosis, dysrhythmias, hypotension	Acute respiratory failure, drug overdose, chest wall trauma, asphyxiation, CNS trauma, impaired muscle of respiration
<i>Respiratory Alkalosis</i>	↑	↓	No change ↓*	Paresthesia (fingers), dizziness, lethargy, confusion	Hyperventilation, salicylate poisoning, hypoxia with pneumonia, pulmonary edema, gram-negative sepsis, CNS lesion, inappropriate mechanical ventilation
*Compensatory response					



## Parenteral Solutions—Fast Facts

### Dextrose Solutions

- 1600 calories needed daily for an adult at bed rest, which does not allow for fever or other increased metabolism needs.
- 5% dextrose in water = 5 g dextrose in 100 mL
- 1 L of 5% dextrose = 50 g of dextrose
- Provided as 2.5%, 5%, 10%, 20%, 30%, 50%, and 70%
- Hypotonic dextrose solutions hydrate the intracellular compartment
- Hypertonic dextrose solutions pull water from the intracellular compartment, decreasing swelling
- Before any medication is added to a dextrose solution, compatibility information should be checked

### Sodium Chloride Solutions

- Provide for ECF replacement
- Available in 0.25%, 0.33%, 0.45%, 0.9%, 3%, and 5%
- During times of stress, the body retains sodium, adding to hypernatremia
- Hypotonic saline is 0.45% or less; can be used to supply normal daily salt and water requirements safely
- 0.9% sodium chloride is the only solution to be used with blood components
- Hypertonic sodium chloride (3% and 5%) can be dangerous when administered incorrectly

### Hydrating Solutions

- Combination of dextrose and hypotonic sodium chloride
- Hydrates patients in dehydrated states
- Promotes diuresis—used for fluid challenge, check kidney function
- Potassium free

### Multiple Electrolyte Solutions

#### Lactated Ringer's

- Solution that most parallels the body's extracellular electrolyte content
- Used to replace fluid loss from burns, bile, and diarrhea
- Contains bicarbonate precursor to assist in prevention of acidosis
- Should not be used in patients with impaired lactate metabolism

**Alkalizing Solutions**

- 1/6 molar sodium lactate and 5% sodium bicarbonate injection
- Used for metabolic acidosis

**Acidifying Solutions**

- Ammonium chloride
- Treat metabolic alkalosis
- Use with caution in patients with severe hepatic disease

**Colloid Solutions****Dextran**

- Polysaccharide
- Low molecular weight Dextran (Dextran 40) and high molecular weight Dextran (Dextran 70)
- Substitute for plasma expansion
- Contraindicated for severe bleeding disorders

**Albumin**

- Available as 5% or 25%
- 5% is osmotically and oncologically equal to plasma
- 25% equal to 500 mL of plasma
- Used for maintenance of blood volume

**Mannitol**

- Sugar alcohol substance
- Available from 5% to 25%
- Promotes diuresis
- Reduces intracranial pressure and cerebral edema

**Hetastarch**

- Hydroxyethyl glucose; synthetic colloid made from starch
- Hespan 6% or 10%
- Does not interfere with blood typing and cross-matching as do other colloidal solutions
- Possibility of allergic reaction
- Use cautiously in patient whose conditions cause fluid retention

## Intravenous Solutions Chart

Solutions	Osmolarity	Indications	Precautions
<b>Dextrose</b> 2.5% 5% 10%, 20%, 50%, 70%	Hypotonic Isotonic Hypertonic	Spares body protein Provides calories Provides free water Acts as a diluent for IV drugs Treats dehydration Treats hyperkalemia	Possible compromise of glucose tolerance Does not provide any electrolytes May cause vein irritation, water intoxication Hypertonic solutions may cause hyperglycemia, osmotic diuresis
<b>Sodium Chloride</b> 0.25% 0.45% half-strength 0.9% full strength 3% 5%	Hypotonic Isotonic Hypertonic	Replaces ECF and electrolytes Replaces sodium and chloride Treats hyperosmolar diabetes Acts as diluent for IV drugs Used to initiate blood products Replaces severe sodium and chloride deficits Irrigant for intraavascular devices	Hyponatremia; calorie depletion; hypernatremia or hyperchloremia; circulatory overload; deficit of other electrolyte Can induce hyperchloremic acidosis due to loss of bicarbonate ions Does not provide free water or calories

*(Continued on the following page)*

## Intravenous Solutions Chart *(Continued)*

Solutions	Osmolarity	Indications	Precautions
<p><i>Hydrating Solutions</i>                      5% D/0.25% NaCl 5%                      D/0.45% NaCl 5%                      D/0.9% NaCl</p>	<p>Isotonic                      Hypertonic</p>	<p>Assess kidney function                      Hydrate cells                      Promote diuresis                      Supply some calories                      Reduce nitrogen depletion                      Used as plasma expander</p>	<p>Use with caution in patients with edema and those with cardiac, renal, or liver disease.                      Do not use in patients allergic to corn.</p>
<p><i>Multiple Electrolyte Lactated Ringer's</i>                      5% D/LR</p>	<p>Isotonic                      Hypertonic</p>	<p>Treats mild metabolic acidosis                      Replaces fluid losses from burns and trauma                      Replaces fluid losses from alimentary tract                      Rehydrates in all types of dehydration</p>	<p>Contraindicated in patients with lactic acidosis                      Circulatory overload</p>
<p><i>Plasma Expanders</i>                      Dextran 70 (6%) in water                      Dextran 40 (10%) in water</p>	<p>Isotonic</p>	<p>Provides plasma expansion                      Treats shock                      Prevents venous thrombosis during surgery</p>	<p>Hypersensitivity reactions                      Increased risk of bleeding                      *Do not add any medications to dextran solutions</p>

## Intravenous Solutions Chart


Solutions	Osmolarity	Indications	Precautions
<i>10% Mannitol</i> <i>20% Mannitol</i>	Hypertonic	Reduces introcular pressure, reduces cerebral edema Promotes diuresis of toxic substances	Hypervolemia Extravasation Skin irritation Tissue necrosis Interferes with laboratory testing
<i>5% Albumin</i> <i>25% Albumin</i>		Restores circulatory dynamics Counteracts shock Provides protein Treats hyperbilirubinemia	Allergic reactions Circulatory overload Alteration in laboratory tests Due to heat during preparation, viral disease transmission is eliminated

## Notes

**Contents: PERIPHERAL**

Skin	34
Venous System	35
Anatomy of a Vein	35
Anatomy of the Peripheral Vasculature	36
Superficial Vessels of the Forearm	37
Selection of Gauge of Catheter and Insertion Site	37
Phillips 15-Step Venipuncture Method	39
Stabilizing the Catheter	47
Applying a Dressing	50
Procedure: Administration of Piggyback Secondary Infusion	51
Flushing Intermittent Infusion Devices	52
Flushing IV Catheters	53
Local Anesthesia	54
IV Piggyback (IVPB) Setup	55
Local Complications of Peripheral IV Therapy	60
Systemic Complications of Peripheral IV Therapy	61
Phlebitis Scale	63
Calculation of Phlebitis Rates	63
Infiltration Scale	63
Factors in Flow Rate Control	64
Complications of Starting/Maintaining IVs	64
Extravasation Antidote Chart	65

## Skin



The skin consists of two main layers, the epidermis and dermis

- Epidermis composed of squamous cells: normally 5–7 cells thick as age decreases layers of cells and thins
- Dermis: thicker layer consists of blood vessels, hair follicles, sweat glands, small muscles, and nerves



- Dermis reacts quickly to painful stimuli, temperature changes, and pressure sensation. Most painful layer during venipuncture!
- Sensory receptors are located in dermis
  - Mechanoreceptors—process skin tactile sensations (vein palpation)
  - Thermoreceptors—process cold, warmth, and pain (application of heat and cold)
  - Nociceptors—process pain (insertion of catheter)

## Venous System


Venous blood flows slower in periphery and increases in turbulence in the larger veins of the thorax

Cephalic and basilic veins: 45–90 mL/min

Subclavian vein: 150–300 mL/min

Superior vena cava: 2000 mL/min

## Anatomy of a Vein



### Key Points

#### Tunica Adventitia

- Outermost layer
- Supports and surrounds a vessel
- Blood supply of this layer called vasa vasorum—in IV therapy when you get a small amount of blood flow but cannot thread the catheter, you are in this layer of the vein!


#### Tunica Media

- Middle layer composed of muscular and elastic tissue
- Contains nerve fibers for vasoconstriction and vasodilation
- Collapses or distends as pressure decreases or increases


#### Tunica Intima

- Innermost layer
- Has one thin layer of cells—endothelial lining
- Any roughening of this layer fosters the process of thrombosis formation

### Anatomy of the Peripheral Vasculature



## Superficial Vessels of the Forearm



## Selection of Gauge of Catheter and Insertion Site

Vein Location	Size of Catheter	Considerations
<i>Digital: Lateral and dorsal portions of fingers</i>	Small gauge: 20–22 g	Use only solutions that are isotonic Use a padded tongue blade to splint the catheter

## Selection of Gauge of Catheter and Insertion Site

Vein Location	Size of Catheter	Considerations
<i>Metacarpal: Dorsum of hand</i>	20–22 g; 3/4–1 inch in length	Good site to begin therapy Easy to visualize Avoid if infusing antibiotics, potassium chloride, or chemotherapeutic agents!
<i>Cephalic: Radial portion of lower arm along radial bone of forearm</i>	18–22 g	Large vein, easy to access Useful for infusing blood and chemically irritating medications
<i>Basilic: Ulnar aspect of lower arm, runs up ulnar bone</i>	18–22 g	Difficult to access Large vein, easily palpated but moves easily; stabilizes with traction Vein dilates with multiple tourniquet technique
<i>Upper cephalic: Radial aspect of upper arm above elbow</i>	16–20 g	Difficult to visualize Excellent site for confused patients
<i>Median antecubital veins: In the bend of the elbow; three veins Median basilic Median cubital Median cephalic</i>	16–20 g	Should be reserved for blood draws Uncomfortable placement site owing to arm extending in an unnatural position Area difficult to splint with armboard If used in an emergency situation, change site within 24 hours

## Phillips 15-Step Venipuncture Method

### Pre-Catheterization

1. Check physician's order
2. Hand hygiene procedures
3. Prepare equipment and inspect for integrity
4. Patient assessment and psychological preparation
5. Site selection and vein dilation

### Catheterization

6. Needle selection
7. Glove
8. Prepare site
9. Insertion of catheter into vein
10. Catheter stabilization and dressing management

### Post-Catheterization

11. Label solution, tubing, and catheter site
12. Disposal of equipment
13. Patient education
14. Rate calculation
15. Documentation

### Step 1: Check Physician's Order

A physician's order is necessary to initiate IV therapy. The physician's order should include:

- Type of solution
- Route of administration
- Amount to be infused either hourly or 24-hour volume
- Rate of infusion
- Duration of infusion
- Physician's signature

### Step 2: Hand Hygiene Procedures

#### Indications for handwashing and hand antisepsis

- When hands are visibly dirty or contaminated with blood or other body fluids, wash hands with either a nonantimicrobial soap and water or an antimicrobial soap and water.

- If hands are not visibly soiled, use an alcohol-based hand rub to avoid routinely contaminating hands in all other clinical situations.
- Decontaminate hands before having direct contact with patients
- Do not wear artificial fingernails or extenders when having direct contact with patients at high risk

(CDC, 2002)

### Step 3: Equipment Preparation

- Inspect solution container for integrity
  - Glass—Hold up to light to look for cracks, clarity, particulate contamination, and expiration date
  - Plastic—Squeeze to check for pinholes, clarity, particulate contamination, and expiration date
- Inspect administration set
  - Choose the appropriate set: vented or nonvented
- Gather venipuncture and dressing supplies
  - Catheter (22 g, 20 g, or 28 g most common)
  - Dressing (gauze or TSM)
  - Tape: 1-inch paper
  - Prepping solution
  - Gloves
  - 2×2 gauze

### Step 4: Patient Assessment and Psychological Preparation

- Provide privacy
- Evaluate the patient preparedness for IV procedure by talking with patient before assessing veins

### Things to know

- Patient's medical diagnosis.
- History of chronic disease that places patient at risk for complications.
- History of vasovagal reactions during venipuncture or when blood is seen.
- Has the patient had vascular access devices?
- Will the patient be going home with the catheter?

- If cultural barrier exists, take more time; speak slowly and distinctly but not louder. Use pictures. Keep messages simple, and use interpreter to improve communication.
- Assess both arms and hand prior to choosing appropriate vein.
- Choose the lowest best site for size catheter being inserted and type of therapy the patient will receive.

### **Step 5: Site Selection and Vein Dilatation**

#### **Factors to consider before venipunctures:**

- **Type of solution** to be infused—Hypertonic solutions and medications are irritating to vein.
- **Condition of vein**—Use soft, straight, bouncy vein; if you run your finger down the vein and it feels like a cat's tail—avoid! Avoid veins near previously infected areas.
- **Duration of therapy**—Choose a vein that can support IV therapy for 72–96 hours.
- **Catheter size**—Hemodilution is important. The gauge of the catheter should be as small as possible.
- **Patient age**—Elderly and children need additional time for assessment and management of insertion.
- **Patient activity**—Ambulatory patients using crutches or walker need catheter placement above the wrist.
- **Presence of disease or previous surgery**—Patients with vascular disease or dehydration may have limited venous access. If a patient has a condition causing poor vascular return (mastectomy, stroke), the affected side **must be avoided**.
- Presence of shunts or graft—Do **not** use the arm or hand that has a patent graft or shunt for dialysis.
- **Patient receiving anticoagulation therapy**  
Patients receiving anticoagulant therapy have a propensity to bleed.  
Local ecchymoses and major hemorrhagic complications can be avoided if the nurse is aware of the anticoagulant therapy.  
Precautions: Minimal tourniquet pressure; use the smallest catheter that is appropriate for therapy; use care in removing dressing.

- Patient with allergies
  - Identify allergies
  - Iodine—avoid povidone-iodine as skin preparation
  - Latex—set up latex allergy cart
  - Question regarding allergies to medications, foods, animals, and environmental substances

### Vein dilation techniques

- **Tourniquet**—Latex or nonlatex used most frequently. Placed 6–8 inches above the venipuncture site. If BP high, move farther from venipuncture site. If BP low, move as close as possible without risking site contamination.
- **Gravity**—Position the extremity lower than the heart.
- **Fist clenching**—Instruct patient to open and close his/her fist.
- **Tapping vein**—Using thumb and second finger, flick the vein; this releases histamines beneath the skin and causes dilation (do not slap vein).
- **Warm compresses**—10 minutes maximum. *Do not use microwave!*
- **Blood pressure cuff**—Inflate to 300 mm Hg; great for fragile veins
- **Multiple tourniquet technique**—Use 2 to 3 latex tourniquets; apply one high on arm and leave for 2 minutes; apply second at midarm below antecubital fossa; collateral veins should appear; apply third if needed.

### Tips for selecting veins

- Suitable vein should feel relatively smooth and pliable, with valves well spaced
- Start with distal veins and work proximally
- Veins that feel bumpy (like running your finger over a cat's tail) are usually thrombosed or extremely valvular
- Veins will be difficult to stabilize in a patient who has recently lost weight
- Sclerotic veins are common among narcotic addicts
- Dialysis patients usually know which veins are good for venipunctures



**Step 6: Needle Selection****Recommended gauges**

- 16–18 g: Trauma
- 18–20 g: Infusion of hypertonic or isotonic solutions
- 18–20 g: Blood administration (18 g preferred)
- 22–24 g: Pediatric patients
- 22 g: Fragile veins in elderly person (if unable to place 20 g)
  - The tip of the catheter should be inspected for integrity prior to venipuncture
  - Only two attempts at venipuncture are recommended

**Step 7: Gloving**

Standard precautions require gloves to be worn during placement of an IV catheter.

**Step 8: Site Preparation****Key points**

- Do not shave site—Remove hair with scissors or clippers only
- Depilatories not recommended—Potential for allergic reaction
- Cleanse insertion site with one of the following solutions:
  - 2% Chlorhexidine gluconate (preferred)
  - Iodophor (povidone-iodine)
  - 70% Isopropyl alcohol
  - Tincture of iodine 2%

**Standard of practice**


Do not apply 70% isopropyl alcohol after povidone-iodine preparation. Alcohol negates the effect of povidone-iodine (INS 2000, 47).

**Technique:** Apply antimicrobial solution, working from center outward in a circular motion for 2–3 inches for 20 seconds, using friction.

**Step 9: Vein Entry****Two methods of venipuncture**


- Direct method
- Indirect method

**Step a**—Pull skin below puncture site to stabilize the skin and prevent the vein rolling



**Step b**—Grasp flashback chamber on catheter

**Step c**—Insert needle **bevel up** at 30–45 degree angle



**Step d**—Insert catheter by direct or indirect method with steady motion


**Direct: One-Step Method**

Insert catheter directly over vein  
Penetrate all layers of vein in one motion

**Indirect: Two-Step Method**

Insert catheter at a 30-45 degree angle to skin alongside vein;  
gently insert catheter distal to point at which needle will enter vein;  
maintain parallel alignment and advance through the subcutaneous tissue


Relocate the vein and decrease the angle as the catheter stylet enters vein




**Step e**—After bevel enters vein and blood flashback occurs, lower angle of catheter and stylet as one unit and advance into vein

**Note:** A steady backflow of blood indicates successful entry.

**Step f**—After vein is entered, cautiously advance catheter into vein lumen. Hold catheter hub with your thumb and middle finger and use your index finger to advance catheter, maintaining skin traction. A one-handed technique is recommended to advance catheter off the stylet.



**Step f**

**Step h**

**Step g**—While stylet is still partially inside catheter, release tourniquet.

**Step h**—Remove stylet

**Step i**—Connect adaptor on administration set or PRN device to catheter hub

### **Step 10: Catheterization**

#### **Catheter stabilization and dressing management**


##### Catheter Stabilization

##### Key Points


- Catheter should be stabilized in a manner that does not interfere with visualization.
- Methods appropriate for stabilization of catheter hub
  - U method
  - H method
  - Chevron method

**STABILIZING THE CATHETER\***


U Method



H Method



Chevron Method

**Use for  
Winged Set**

1. Cut three strips of  $\frac{1}{2}$ -in tape. With sticky side up, place one strip under tubing.
2. Bring each side of the tape up, folding it over the wings of the needle. Press it down, parallel with the tubing.
3. Loop the tubing and secure it with a piece of 1-in tape.

**Use for  
Winged Set**

1. Cut three strips of 1-in tape.
2. Place one strip of tape over each wing, keeping the tape parallel with the needle.
3. Place another strip of tape perpendicular to the first two. Place over the wings to stabilize wings and hub.

**Use for  
Winged Set**

1. Cover the venipuncture with transparent dressing or  $2 \times 2$  gauze dressing.
2. Cut a long 5- to 6-in strip of  $\frac{1}{2}$ -in tape. Place one strip of tape, sticky side under hub, parallel with the dressing.
3. Cross the end of the tape over the opposite side of the needle so that the tape sticks to the patient's skin.
4. Apply a piece of 1-in tape across the wings of the chevron. Loop the tubing and secure it with another piece of 1-in tape.

\*For all methods, include on the last piece of tape the date, time of insertion, size of gauge, length of needle or catheter, and your initials.

**Dressing management**

Types of dressings acceptable for peripheral catheter

- Gauze dressing with tape
- Transparent semipermeable dressing (TSM)

**Standards of practice**

- Gauze dressings should be changed every 48 hours on peripheral sites (INS 2000, 50)
- The use of nonocclusive-type adhesive bandage strip in place of dressing not recommended
- TSM dressing can be changed when catheter is changed (72–96 hr)

**Step 11: Post-Catheterization****Labeling****Insertion site**

The venipuncture site should be labeled:

- Date and time
- Type and length of catheter
- Nurse's initials

**Administration set**

- Label according to agency policy: label should have date on which administration set must be changed

**Solution container**

- Place a time strip on all parenteral solutions
- Any additives must have a clear label applied to bag

**Step 12: Equipment Disposal****Standard of practice**

Needles and stylets shall be disposed of in nonpermeable, tamper-proof containers (INS, 2000, 31)

Dispose of all paper and plastic equipment in a biohazard container

**Step 13: Patient Education**

Patient must receive information on all aspects of their care. After catheter is stabilized, dressing is applied, and labeling complete:

- Inform regarding any limitations of movement or mobility
- Explain all alarms if EID is used
- Instruct to call for assistance if venipuncture site becomes tender or sore or if redness or swelling develops
- Advise that site will be checked every shift by the nurse

### **Home care**

Comprehensive education to patient and caregiver includes the behavioral domains of cognitive, affective, and psychomotor along with written set of instructions on treatment.

### **Step 14: Rate Calculation**

Refer to section in Basics for rate calculation information.

Do not leave patient care environment until rate is calculated and adjusted.


### **Step 15: Documentation**

Documentation of IV therapy procedures include:


- Date and time of insertion
- Manufacturer's brand name and style of device
- The gauge and length of the device
- Specific name and location of the accessed vein
- Number of attempts for a successful IV start
- Infusing by gravity or EID
- Any add-on devices
- The patient's specific comments related to the procedure
- Signature

## Applying a Dressing


Step 1: Cover the insertion site and catheter hub with the transparent dressing.



Step 2: Pinch the transparent dressing around the catheter hub to secure the hub.



Step 3: Label the insertion site, noting the catheter gauge, date and time of insertion, and initials of the person who performed the venipuncture.



(Figures courtesy of Critikon, a Johnson & Johnson Company.)



**Procedure: Administration of Piggyback Secondary Infusion****Equipment: Gloves, medication bag, secondary administration set, alcohol swabs**

- Verify physician order
- Educate patient regarding purpose of medication
- Follow hand hygiene procedures
- Observe standard precautions
- Check compatibility of medication with IV solution, and check expiration date
- Add drug to secondary IV infusion solution if appropriate, or remove piggyback medication prepared in pharmacy from refrigerator 10–15 minutes prior to infusion
- Secure secondary administration set onto piggyback solution container. Prime the set.
- Confirm patient's identity and verify allergy status
- Don gloves
- Swab injection port (port closest to drip chamber) with alcohol
- Hang secondary piggyback set container
- Insert needleless tip from secondary line into injection port. (Most systems have Luer lock device that secures the secondary administration set to the primary set port)
- Lower primary bag with the extension hook that is contained in the secondary administration box (primary set must hang lower than secondary)
- Open clamp and adjust drip rate
- Document procedure and medication administration

**Note:** As secondary infusion begins, the back check valve in the primary administration set will close from pressure, stopping the primary infusion.

## Flushing Intermittent Infusion Devices

Intermittent infusion devices referred to as PRN devices, locking devices, heparin locks, saline locks. All use a resealable device! Two methods of maintaining patency of locking devices: sodium chloride (saline flush) and heparin lock flush.

### Procedure: Saline Flush—Use With Peripheral Devices

*Flushing Supplies:* Gloves, antiseptic solution swabs, preservative-free 0.9% sodium chloride (saline), syringes (3 mL or 5 mL)

- Follow hand hygiene procedures
- Don gloves
- Observe standard precautions
- Cleanse port with appropriate antiseptic solution
- Insert saline-filled syringe to catheter via insertion into locking device
- Slowly aspirate until positive blood return is obtained to confirm patency
- Slowly inject flush (1 mL)
- Disconnect syringe and attach medication syringe
- Administer medication slowly
- Disconnect medication syringe; attach saline syringe
- Flush with saline, maintaining positive pressure
- Disconnect syringe from access port
- Document in patient record

**Note:** Most peripheral lines are maintained with sodium chloride flush

## Flushing IV Catheters

Catheter Type	Solution	Strength	Frequency
<b>Peripheral Catheters (Open Ended)</b>			
Peripheral IV catheter	Normal saline	n/a	3 mL daily and PRN
Midline catheter (each lumen if multiple)	Heparin	10 units/mL	5 mL daily and PRN
<b>Central Venous Catheters (CVC)</b>			
Valved-tip catheters (Groshong)	Normal saline	n/a	5 mL per lumen weekly and PRN
Open-ended PICC lines	Heparin	10 units/mL	5 mL per lumen daily and PRN
Tunneled catheters (Hickman, Broviac)	Heparin	100 units/mL	5 mL per lumen daily and PRN
<b>Implanted Port Catheters</b>			
Groshong Port-a-Cath (when accessed)	Heparin	100 units/mL	5 mL daily and PRN
<b>Solution Used to Flush a Catheter</b>			
Valved-tip catheters require only saline flushes; however, the use of heparin is not contraindicated. All other central lines require heparin flushes to minimize fibrin collection and clot formation.			
<b>Syringe Selection</b>			
The smaller the syringe size, the greater the pressure in PSI. Greater PSI pressure increases potential for catheter damage. Therefore, a syringe size of <b>10mL</b> or greater is recommended for central-line flushes.			
<b>Positive-Pressure Flushing of Valved-Tip Catheters</b>			
<b>Important:</b> To reduce potential for blood backflow into the catheter tip, which promotes clot formation and catheter occlusion, always remove needles or needleless caps slowly while injecting the last 0.5 mL of saline.			
<b>"SAS" Technique: Flush with Saline, Administer Med, Flush with Saline</b>			

### Procedure: Heparin Lock Flush

Used most frequently with central venous access devices (CVADs)

SASH Method (Saline, Administration, Saline, Heparin)

*Flushing Supplies:* Antiseptic solution swabs, preservative-free 0.9% sodium chloride injection, heparin 10 U, 100- $\mu$ /mL vials, syringes (10 mL), gloves, and sharps container

- Follow hand hygiene procedures
- Don gloves
- Observe standard precautions
- Cleanse injection port with appropriate antiseptic solution
- Connect saline-filled syringe to injection port
- Slowly aspirate until positive blood obtained, confirming catheter patency
- Flush with saline
- Cleanse port with appropriate antiseptic solution
- Connect medication to injection port
- Administer medication
- Disconnect medication from port
- Cleanse injection/access port with antiseptic solution
- Connect second saline-filled syringe to injection port
- Flush with saline
- Disinfect port with antiseptic solution
- Connect heparin-filled syringe to injection port and slowly aspirate to reconfirm positive blood aspirate
- Slowly inject flush, maintaining positive pressure
- Document heparin flush in patient record

### Local Anesthesia

Anesthesia is used to provide a localized effect during vascular access. A physician's verbal or written order is required, and organization policy must be followed.

Types of local anesthetics:

- Transdermal analgesic cream

- Iontophoresis of lidocaine hydrochloride 2% with epinephrine 1:1000,000 topical solution
- Intradermal injection of lidocaine hydrochloride 1%

### Procedure: Transdermal (Topical) Analgesic Cream

*Equipment:* Transdermal cream, occlusive dressing, single-use alcohol swabs

- Follow hand hygiene procedures
- Don gloves
- Observe standard precautions
- Follow manufacturer's guidelines
- Assess and select intended venipuncture site
- Cleanse site with antiseptic solution (usually alcohol)
- Cover with transparent semipermeable membrane (TSM) dressing for manufacturer's recommended time (30–60 min)
- Remove dressing and remaining cream
- Cleanse site with antiseptic solution, and begin venipuncture procedure
- Include use of transdermal cream in documentation


### Procedure: Intradermal Anesthetic—Lidocaine 1%

*Equipment:* Gloves, intradermal anesthetics (lidocaine 1%), single-use alcohol swabs, gauze pads, tuberculin 1-mL syringe, sharps container

- Follow hand hygiene procedures
- Don gloves
- Observe standard precautions
- Cleanse site with alcohol and allow to dry
- Draw 0.3 mL of lidocaine 1% into tuberculin syringe
- With needle bevel up, gently insert needle intradermally above intended venipuncture site
- Inject 0.3-cc anesthetic to form wheal
- Remove needle and discard syringe in sharps container
- Include use of lidocaine in documentation procedure

## IV Piggyback (IVPB) Setup

- The piggyback bag must be higher than the IV.
- To do this, use an **extension hook**.
- Use the most proximal access port on primary line.
- Adjust piggyback stopcock to desired rate.
- After infusion is complete, the primary IV bag will begin to drip again. Ensure primary drip rate.



### Procedure: Medication Administration—Direct IV Push

*Equipment:* Gloves, three 3-cc syringes, one for medication, two for sodium chloride flush; medication; and filter needle if appropriate

- Verify physician order
- Educate patient regarding purpose of medication
- Follow hand hygiene procedures

- Observe standard precautions
- Check compatibility of medication with IV solution, and check expiration date
- Dilute opioid analgesics, and follow manufacturer's recommendation for administration
- Don gloves
- Cleanse lowest Y port, if using primary line, or resealable lock on locking device with antiseptic solution. Check for patency. If drug is incompatible with primary solution, flush catheter with 0.9% sodium chloride before and after administration of medication (INS, 2000, 73)
- Insert syringe into medication port
- Pinch tubing to primary solution if using primary line
- Inject one-fourth of medication into patient over a 15- to 20-second period
- Watch patient for any adverse effects
- Repeat above steps, delivering one-fourth of drug each time for three more times
- When the entire desired drug is delivered, remove syringe from port
- Flush catheter, following saline lock flush guidelines
- Document procedure and how patient tolerated medication administration

### Discontinuation of IV Catheter

*Equipment:* Gloves, 70% isopropyl alcohol swabs, 2 x 2 inch sterile gauze, tape, Band-Aids, sharps container

- Verify physician order
- Check patient identification
- Explain procedure to patient
- Follow hand hygiene procedures
- Observe standard precautions
- Clamp infusion administration set and turn off EID
- Don gloves

- Remove all tape and carefully loosen skin from edges of TSM dressing over the IV site (use stretch method or alcohol over TSM dressing to loosen material)
- Place 2 x 2 inch sterile gauze over the IV insertion site and slowly withdraw catheter in one motion; do not apply pressure over catheter while removing; once catheter is removed, place on paper towel next to bed
- Apply firm pressure over venipuncture site once catheter has been removed
- Examine catheter for integrity and intactness
- Dispose of catheter in sharps container
- Once any signs of bleeding have stopped, apply Band-Aid or sterile 2 x 2 gauze and tape over site
- Assess site for signs of redness, swelling, or purulent drainage
- If patient is being discharged, educate about site care
- Document site assessment and catheter integrity



## Local Complications of Peripheral IV Therapy

Complication	Signs & Symptoms	Treatment	Prevention
<i>Hematoma</i>	Ecchymoses Swelling Inability to advance catheter Resistance during flushing	Remove catheter Apply pressure with 2 × 2 Elevate extremity	Use indirect method of venipuncture Apply tourniquet just before venipuncture
<i>Thrombosis</i>	Slowed or stopped infusion Fever/malaise Inability to flush catheter	Discontinue catheter Apply cold compresses to site Assess for circulatory impairment	Use pumps Choose micro-drip sets with gravity flow if rate is below 50 mL/hr Avoid flexion areas
<i>Phlebitis</i>	Redness at site Site warm to touch Local swelling Pain Palpable cord Sluggish infusion rate	Use phlebitis scale for documentation Discontinue catheter Apply cold compresses initially; then warm Consult physician if 3+	Use larger veins for hypertonic solutions Choose smallest catheter appropriate Good hand hygiene Add buffer to irritating solutions Change solutions containers every 24 hr Rotate infusion sites every 72–96 hr

*(Continued on the following page)*

## Local Complications of Peripheral IV Therapy (Continued)

Complication	Signs & Symptoms	Treatment	Prevention
<i>Infiltration (extravasation)</i>	Coolness of skin at site Taut skin Dependent edema Backflow of blood absent Infusion rate slowing	Use infiltration scale Discontinue catheter Apply cool compresses Elevate extremity slightly Follow extravasation guidelines Have antidote available	Stabilize catheter Place catheter in appropriate site Avoid antecubital fossa
<i>Local infection</i>	Redness and swelling at site Possible exudate Increase WBC count Elevated T lymphocytes	Discontinue catheter and culture site and catheter Apply sterile dressing over site Administer antibiotics if ordered	Inspect all solutions Good technique during venipuncture and site maintenance
<i>Venous spasm</i>	Sharp pain at site Slowing of infusion	Apply warm compress to site Restart infusion only if spasm continues	Thorough history Verify allergies Proper patient identification Warm solutions with appropriate warming device if appropriate

## Systemic Complications of Peripheral IV Therapy

Complication	Signs & Symptoms	Treatment	Prevention
<i>Septicemia</i>	Fluctuating temperature Profuse sweating Nausea/vomiting Diarrhea Abdominal pain Tachycardia Hypotension Altered mental status	Restart new IV system Obtain cultures Notify physician Initiate antimicrobial therapy as ordered Monitor patient closely	Good hand hygiene Careful inspection of fluids Use Luer locks Cover infusion sites with appropriate dressings Follow standards of practice related to rotation of sites/hang time of infusions Use appropriate preparation solutions
<i>Fluid overload</i>	Weight gain Puffy eyelids Edema Hypertension Changes in I&O Rise in CVP Shortness of breath Crackles in lungs Distended neck veins	Decrease IV flow rate Place patient in high Fowler's position Keep patient warm Monitor vital signs Administer oxygen Consider changing to microdrip set	Monitor infusion flow at prescribed rate Monitor I&O Know patient's cardiovascular history Do not "catch up" infusion—recalibrate

*(Continued on the following page)*

## Systemic Complications of Peripheral IV Therapy *(Continued)*

Complication	Signs & Symptoms	Treatment	Prevention
<i>Air embolism</i>	Lightheadedness Dyspnea, cyanosis, tachypnea, expiratory wheezes, cough Mill wheel murmur, chest pain, hypotension Changes in mental status Coma	Call for help! Place patient in Trendelenburg position Administer oxygen Monitor vital signs Notify physician	Remove all air from administration sets Use Luer locks Attach piggyback to appropriate port
<i>Speed shock</i>	Dizziness Facial flushing Headache Tightness in chest Hypotension Irregular pulse Progression of shock	Call for help! Give antidote or resuscitation medications	Reduce the size of drops by using microdrip set Use EID Monitor infusion sites Dilute IV push medications if possible; give slowly
<i>Catheter embolism</i>	Sharp sudden pain at IV site Rough, uneven catheter noted on removal Chest pain Tachycardia	Apply tourniquet above elbow Contact physician Start new IV Measure remainder of catheter	Use radiopaque catheters! Do not apply pressure over site. Avoid joint flexions. Never reinsert stylet that has been removed from sheath.

## Phlebitis Scale

Grade	Clinical Criteria
0	No clinical symptoms
1	Erythema at access site with or without pain
2	Pain at access site with erythema and/or edema
3	Pain at access site with erythema and/or edema, streak formation, and palpable venous cord
4	Pain at access site with erythema and/or edema, streak formation, palpable venous cord >1 inch in length, purulent drainage

Source: Revised Standards of Practice (2000). Infusion Nurses Society, with permission.

### Calculation of Phlebitis Rates

The peripheral phlebitis incidence rate should be calculated according to a standard formula:

$$\frac{\text{Number of phlebitis incidents}}{\text{Total number of IV peripheral lines}} \times 100 = \% \text{ of Peripheral phlebitis}$$

## Infiltration Scale

Grade	Clinical Criteria
0	No clinical symptoms
1	Skin blanched, edema <1 inch, cool to touch, with or without pain
2	Skin blanched, edema 1–6 inches, cool to touch, with or without pain
3	Skin blanched and translucent, gross edema >6 inches, cool to touch, mild to moderate pain, possible numbness
4	Skin blanched and translucent, skin tight, leaking, gross edema >6 inches, deep-pitting tissue edema, circulatory impairment, moderate to severe pain

Source: Revised Standards of Practice (2000). Infusion Nurses Society, with permission.

## Factors in Flow Rate Control

Patient Related	Vein Related
Patient or family manipulation Patient blood pressure	Infiltration Phlebitis  Venous spasm
Administration Set Related	Clot Formation
"Cold flow" of plastic set Drop formation rate Final in-line filters Kinked or pinched set Rate of fluid flow Slipping of roller clamp–gravity set EID malfunction	Needle or catheter position  <b>Other</b> Height of IV standard Bed position

## Complications of Starting/Maintaining IVs

Infiltration	Phlebitis
<b>Assessment:</b> Swelling; tenderness; decreased or no infusion rate; blanching of skin; site is cool to touch.	<b>Assessment:</b> Classic sign is red line along course of vein; other signs include redness, heat, swelling, and tenderness.
<b>Interventions:</b> D/C IV, and restart in a new site. Apply warm compress to affected area.	<b>Interventions:</b> D/C IV, and restart in a new site. Apply warm compress to affected area.

## Extravasation Antidote Chart

Drug Class	Medication	Extravasation Symptoms	Antidote & Dose	Nursing Tip
Adrenergic Agents	amrinone (Inocor) dobutamine (Dobutrex) dopamine (Intropin) epinephrine (Adrenalin) isoproterenol (Isuprel) metaraminol (Aramine) methoxamine (Vasoxyl) norepinephrine (Levophed) phenylephrine (NeoSynephrine)	Usually sloughing and tissue necrosis with extravasation	5–10 mg phentolamine mesylate into extravasated area	Discontinue infusion Aspirate any remaining drug with a syringe Apply cold compresses Slightly elevate extremity only if elevation does not cause pain Inject drug into extravasated area, using small intradermal needle (27–25 g)

*(Continued on the following page)*

Extravasation Antidote Chart (Continued)

Drug Class	Medication	Extravasation Symptoms	Antidote & Dose	Nursing Tip
<i>Alkalinizing Agents</i>	sodium bicarbonate tromethamine (Tham-E)	Usually causes ulceration, sloughing, cellulites, and tissue necrosis	Inject 1% procaine to reduce venous spasm Inject 5 to 10 mg phentolamine mesylate into extravasated area <b>Or</b> Inject hyaluronidase (Wydase) 150 U/mL	Discontinue infusion Use small intradermal needle (27–25 g) Apply cold compresses Elevate slightly*



Extravasation Antidote Chart (Continued)

Drug Class	Medication	Extravasation Symptoms	Antidote & Dose	Nursing Tip
<i>Alkylating Agents</i>	carmustine (BCNU) irritant streptozocin (Zancosar) mechlorethamine (nitrogen mustard) vesicant	Usually causes sloughing and tissue necrosis	Inject long-acting dexamethasone or other corticosteroid dimethylsulfoxide (DSM) applied topically <b>OR</b> sodium thiosulfate	Discontinue infusion Apply cold compresses or ice pack (20 min/hr) Elevate slightly* Apply every 3, 4, 6, or 8 hours for 7–14 days. Use ice compresses for 20 min/hr until inflammation

(Continued on the following page)

Extravasation Antidote Chart (Continued)

Drug Class	Medication	Extravasation Symptoms	Antidote & Dose	Nursing Tip
<i>Antihypertensive Agents</i>	nitroprusside sodium (Nipride)		sodium thiosulfate	Discontinue infusion Dilute 4 mL with 6 mL of sterile water; inject 1 to 4 mL through existing catheter; give 1 mL for each milliliter extravasated Use cool compress Elevate slightly*

## Extravasation Antidote Chart

Drug Class	Medication	Extravasation Symptoms	Antidote & Dose	Nursing Tip
<i>Antineoplastic agents (RNA/DNA inhibitors or mitotic inhibitors)</i>	dacarbazine (DTIC) vesicant etoposide (VePeside) irritant vinblastine (Velban) vesicant vincristine (Oncovin) vesicant vindesine (Eldisine) vesicant	Usually causes severe tissue sloughing and necrosis	Inject long-acting dexamethasone or other corticosteroid <b>OR</b> hyaluronidase (Wydase) 150 U/mL	Discontinue infusion Aspirate any remaining drug Apply warm compress Use 27–25 g needle Elevate slightly*

*(Continued on the following page)*

Extravasation Antidote Chart (*Continued*)

Drug Class	Medication	Extravasation Symptoms	Antidote & Dose	Nursing Tip
<i>Antibiotic antineoplastic agents</i>	dactinomycin (Actinomycin D) vesicant daunorubicin (Daunomycin) vesicant doxorubicin (Adriamycin) vesicant idarubicin (Idamycin) vesicant mitomycin C (Mutamycin) vesicant plicamycin (Mithramycin) vesicant	Generally, cause stinging, burning, severe cellulitis, and tissue necrosis	Flush the extravasated area with 0.9% sodium chloride Inject long-acting corticosteroid Inject hyaluronidase (Wydase) (150 U/mL 0.2 mL × 5 SQ throughout the area) Flush with 0.9% sodium chloride Inject long-acting dexamethasone <b>OR</b> Inject hyaluronidase (Wydase) 150 U/mL 0.2 mL × 5 SQ Inject long-acting dexamethasone	Discontinue infusion Aspirate any remaining drug Use small-gauge (27–25g) needle Apply cold compresses Elevate slightly* Discontinue infusion after sodium bicarbonate (neutralizing agent is instilled into catheter) Apply cool compresses

## Extravasation Antidote Chart

Drug Class	Medication	Extravasation Symptoms	Antidote & Dose	Nursing Tip
<i>Electrolyte Solutions</i>	Calcium carbonate Calcium chloride Calcium gluconate Calcium lactate Calcium gluceptate Potassium solutions	Vein irritation that generally causes necrosis, sloughing, cellulitis, and tissue necrosis	Inject hyaluronidase (Wydase) through administration set 150 U/mL 0.2 mL × 5 SQ	Discontinue infusion Apply cool compresses Elevate slightly*
<i>Penicillins</i>	nafcillin (Nafcil; Unipen) ampicillin sodium (Unasyn) azlocillin sodium (Azlin)	Sterile abscesses, thrombophlebitis, and severe pain	Inject hyaluronidase (Wydase) 150 U/mL 0.2 mL	Stop the infusion Aspirate any remaining drug Administer antidote throughout the area to dilute extravasated drug. Use 27–25 g needle subcutaneously

*(Continued on the following page)*

## Extravasation Antidote Chart (Continued)

Drug Class	Medication	Extravasation Symptoms	Antidote & Dose	Nursing Tip
<i>Hypertonic (&gt; 10% Solutions)</i>	Dextrose solutions		Inject hyaluronidase (Wydase) 150 U/mL through administration set 150 U/mL 0.2 mL × 5 SQ	Discontinue infusion Apply cool compresses Elevate slightly <sup>†</sup>

\* Research on small quantities of infiltrated IV solutions followed by magnetic resonance imaging found that hypotonic solutions decreased in volume and hypertonic solutions increased in volume with elevation.

<sup>†</sup> A 4-inch elevation of the extremity made no difference in the rate of fluid reabsorption. Elevating the arm may be uncomfortable for some patients.

## Notes


## Notes



**Contents: CENTRAL**

Anatomy and Physiology Related to IV Practice	76
Anthropometric Measurements of Venous Anatomy	76
Key Terms	77
Injection Ports of Triple-Lumen Catheter	77
Comparison of CVC	78
Percutaneous Catheters	79
PICC	80
Procedure: Irrigating PICC	82
Procedure: Discontinuation of PICC	83
Algorithm for a “stuck” PICC	84
Blood Sampling with PICC	85
Blood Administration with PICC	85
CVTC	86
Irrigating Procedure	87
Procedure: Irrigating CVTC	88
Procedure: Blood Sampling from CVAD	89
Implanted Ports	90
Examples of Port Designs	91
Procedures: Accessing the Port	92
Deaccessing Implanted Port	93
Complications of CVADs	94
Troubleshooting Guide for Occluded Central Catheters	100
Care of CVC	101

## Anatomy and Physiology Related to IV Practice

Anthropometric Measurements  
of Venous Anatomy

Vein	Length, cm	Diameter, mm
Cephalic	38	6
Basilic	24	8
Axillary	13	16
Subclavian	6	19
Right brachiocephalic	2.5	19
Superior vena cava	7	20

## Key Terms


CVAD—central vascular access device

CVC—central venous catheter

CVTC—central venous tunneled catheter

PICC—peripherally inserted central catheter

## Injection Ports of Triple-Lumen Catheter



- Distal port: CVP monitoring and high-volume or viscous fluids, colloids, or medications
- Proximal port: Blood sampling, medications, or blood components administration
- Medial port: Reserved exclusively for TPN
- Fourth port: Infusion of fluids or medications

## Comparison of CVC

Type & Use	Features	Advantages	Disadvantages
<b>Percutaneous use:</b> Intended for days to several weeks	Material: Polyurethane silicone Multiple lumens available	Inserted at bedside Cost-effective Easy to remove	Placement time limited to 7 days Requires sterile dressing changes; daily heparin flushes; catheter may break; requires activity restrictions
<b>PICC use:</b> Up to several months	Material: silicone Lumen: double Groshong valve available	Inserted at bedside by specially trained RN Insertion trays, spare needles, spare catheters, and repair kits available; cost-effective; easy to remove	Requires sterile dressing changes; requires routine heparin flushes except with Groshong valve in place Catheter may break; requires activity restrictions
<b>CVTC use:</b> Long-term: 3 years +	Material: silicone Length: 55–90 cm Gauge: 2.7–19.2 Fr Lumen: multiple Groshong valves available	Long-term access device Requires aseptic dressing changes; clean when site is healed; can be repaired externally; self-care	May require routine heparin flushes, except with Groshong valve; catheter may break; daily to weekly site care; may be difficult to remove

## Comparison of CVC


Type & Use	Features	Advantages	Disadvantages
<b>Implanted Port</b> Use: Long-term: 3 years +	Material: silicone Port: Titanium, stainless steel, plastic Height: 9.8–17.0 mm Width of base: 24–50 mm Lumen: Dual Groshong valve available	Can access dome port from any angle Preattached catheter on port or two- piece system Several catheter port locking devices available No dressing changes; monthly heparin flushes; no activity restrictions	Requires non- coring needle to access; expensive; requires minor surgery to remove

## Percutaneous Catheters

## Key Points

- Inserted at bedside
- Stay in place for 7 days
- Most common site for insertion is infraclavicular approach to subclavian vein
- Patient placed in Trendelenberg position
- Placement must be confirmed by chest x-ray prior to infusion of solutions
- Dressing management: TSM or gauze
- Flush with heparin solution—twice the volume of the catheter

## PICC



## Key Points

- Placement of PICC by RN with specialty training
- Chest radiograph needed to verify placement of PICC tip
- Inserted at bedside
- Stays in place weeks to months
- Sterile procedure (approximately 45 minutes)
- Final placement is in superior vena cava
- Placement must be confirmed by chest x-ray prior to infusion of solutions
- Access through antecubital fossa (basilic, cephalic, median cephalic, and median basilic veins)
- Dressing management: first 24 hours 2 x 2 gauze. After 24 hours change original dressing to gauze or TSM dressing according to organizational policy
- Use 4 Fr or larger for blood administration through PICC
- PICC lines are used successfully with infusion pumps. With 3.0 Fr and smaller PICCs, infusion pumps may be necessary to maintain infusion and patency
- Dual lumen PICCs cannot be repaired

## Irrigating PICC

- Whenever the line needs to be locked
- After every blood draw
- After intermittent medication administration
- After blood or blood component administration
- After TPN

Frequency of flushing procedure depends on organizational policy and patient condition.

Recommendations are:

- Every 4–6 hours for 2 Fr or smaller or after each use
- Every 8–12 hours for larger sizes or after use

## Pulsatile (Push-Pause) Flushing

A rapid succession of pulsatile *push-pause-push-pause* movements exerted on the plunger of the syringe barrel creates a turbulence within the catheter lumen that causes a swirling effect to move residues of fibrin, medication, lipids, or other adherents attached to the catheter lumen.

**Procedure: Irrigating PICC**

**Equipment:** 10-mL syringe, preservative-free 0.9% sodium chloride, gloves, sharps container, antiseptic solution, heparin 10 U–100 U/mL vials, 5 mL (or custom-made kits)

- Verify physician order
- Educate patient on purpose of procedure and site observation after discontinuation
- Follow hand hygiene procedures
- Observe standard precautions
- Follow manufacturer's guidelines for flushing certain CVADs.
- Identify patient
- Don gloves
- Cleanse the central venous catheter injection cap (port) with 70% isopropyl alcohol. Allow to air dry. **Note:** Additional 2% chlorhexidine or povidone-iodine preparation necessary with blunt needle access
- Attach syringe containing 0.9% sodium chloride to the injection port via needleless system
- Aspirate to check patency
- Instruct patient to perform Valsalva maneuver and open the CVC if hub-to-syringe connection
- Irrigate the line with 0.9% sodium chloride using *push-pause* method
- Attach the syringe with the heparinized saline to the injection port (if indicated). Most CVCs require heparin unless closed-end valve such as Groshong or pressure-activated safety valve (PASV)
- Instruct patient to perform Valsalva maneuver and open the CVC clamp if hub to syringe
- Irrigate the line with heparinized saline solution using *push-pause* method
- Document procedure on patient record




**Procedure: Discontinuation of PICC**

Performed by a qualified RN

*Equipment:* 10-mL syringe, sodium chloride, gloves, suture removal set if appropriate, sterile dressing

- Verify physician order
- Educate patient on purpose of procedure and site observation after discontinuation
- Follow hand hygiene procedures
- Observe standard precautions
- Position patient in dorsal recumbent position and abduct the patient's arm
- Don gloves
- Flush the catheter with 0.9% sodium chloride using a 10-mL syringe
- Remove the dressing
- Remove suture if necessary
- Remove any other securement devices if in place
- Withdraw catheter with smooth, gentle pressure in small increments (DO NOT STRETCH CATHETER)
- Cover site with sterile 2 x 2 gauze pressure dressing
- Leave pressure dressing in place for 24 hours
- Measure length of catheter and compare with length recorded before insertion
- Document procedure

## Algorithm for a "stuck" PICC




## Blood Sampling with PICC

- A 4 Fr or larger catheter for blood sampling
- The walls of PICC lines are soft so they collapse easily when strong vacuum is applied; use of gentle touch with syringe method is recommended
- Vacutainers may be used with large catheters

## Blood Administration with PICC

- Blood products may be administered through a 4 Fr or larger PICC
- Flush line thoroughly after administering blood product
- Infusion pump may be necessary

## CVTC



## CVTC

### Key Points

- Intended to be used for months or years; provides long-term venous access
- Composed of polymeric silicone with a Dacron polyester cuff that anchors CVTC in place subcutaneously. Cuff about 2 inches from CVTC's exit site
- Available with Groshong two-way valve
- Available with single, double, triple, or quadruple lumens
- Can be used for many purposes
- Needs daily to weekly site care
- Must be inserted surgically
- Can affect patient's body image
- Should be clamped if malfunction is suspected
- Never use scissors or pins on or near
- Dressing required until site healed or patient hospitalized
- If CVTC leaks or breaks, take a nonserrated clamp and clamp between broken area and exit site; cover with sterile gauze and tape securely
- Protect CVTC when showering or bathing by covering with TSM dressing or clear plastic wrap
- Flush CVTC after blood drawn with 10 mL of 0.9% sodium chloride
- Heparin is used to maintain patency, except for the Groshong catheter

### Irrigating Procedure

Flush the CVTC with twice the catheter volume of heparinized saline. After medication administration or daily maintenance, flush the catheter with saline; then follow with heparinized saline. The use of heparinized saline is usually unnecessary for Groshong valve catheter.

**Procedure: Irrigating CVTC**

**Equipment:** 10-mL syringe, preservative-free 0.9% sodium chloride, gloves, sharps container, antiseptic solution, heparin 10 U–100 U/mL vials, 5 mL (or custom-made kits)

- Verify physician order
- Educate patient on purpose of procedure and site observation after discontinuation
- Follow hand hygiene procedures
- Observe standard precautions
- Aseptically prepare sterile supplies
- Don gloves
- Prepare air-purged heparin flush
- Remove tape holding catheter chest wall
- Cleanse cap-catheter connection point with alcohol for 30 seconds
- Place on sterile 2 x 2 sponge and allow to dry
- Close clamp
- Pick up catheter hub protected by sterile sponge; do not touch cleansed connection
- Attach syringe containing 0.9% sodium chloride to injection port via needleless system
- Aspirate to check patency
- Instruct patient to perform Valsalva maneuver; open the CVC clamp if hub to syringe connection (if not accessing through resealable diaphragm)
- Flush the line with 10–20 mL of 0.9% sodium chloride using *push-pause* method
- Attach the syringe with air-purged heparinized saline to injection port
- Flush the line with heparin. Clamp the line while infusing the last 0.5 mL of solution. **Note:** If a positive-pressure injection port is used, the line does not need to be clamped.
- Document procedure on patient record

**Procedure: Blood Sampling from CVAD**

**Equipment:** 10-mL syringe with 5 mL of preservative-free 0.9% sodium chloride, gloves, sharps container, antiseptic solution, empty 10 mL or larger syringe, 20-mL syringe prefilled with 20 mL of sodium chloride heparin, 10 U–100 U/mL vials, 5 mL (or custom-made kits)

- Verify physician order
- Educate patient on purpose of procedure and site observation after discontinuation
- Follow hand hygiene procedures
- Observe standard precautions
- Discontinue administration of all infusates into the CVAD prior to obtaining blood samples
- Confirm order for laboratory work
- Check patient identification
- Don gloves
- If injection port is not in use: prepare the valve access port with alcohol and allow to dry, followed by 2% CHG or povidone-iodine

**OR**

- If injection port is in use, discontinue IV tubing and cap end to maintain sterility of tubing. Prepare the valve access port with alcohol; allow to dry
- Attach the 10-mL syringe prefilled with 5 mL of NS, then vigorously irrigate with 5 mL of sodium chloride using the pulsatile *push-pause* method
- Draw 5–10 mL of blood into the attached syringe to discard; remove syringe
- Attach sterile syringe and withdraw blood sufficient to fill required collection tubes
- Attach syringe with sample blood to Vacutainer and fill collection tubes
- Irrigate injection port with at least 20 mL of NS using pulsatile *push-pause* method
- Reconnect the infusion line and begin infusion

**OR**

- Attach prefilled air-purged heparinized saline and flush with heparin if catheter does not have Groshong valve
- Label the collection tubes and deliver the sample to the laboratory as soon as integrity of the CVC is ensured
- Dispose of used equipment in sharps container
- Document procedure in patient record





## Implanted Ports

**Key Points**

- Implanted ports are available in one or two septum designs
- Can be placed in SVC, hepatic artery, peritoneal space, and epidural space
- Port made of stainless steel or titanium and has raised edges to facilitate puncture
- Use noncoring (Huber) needle unless manufacturer specifies
- Less risk of infection when used intermittently
- Minimal site care
- Less body image disturbance
- Change administration set every 24 hours
- Dressing and extension tubing and dressing changed every 7 days
- Flush port when not in use with 10–20 mL 0.9% sodium chloride and heparin every 4 weeks
- Change dressing every 72 hours for continuous infusion



## Examples of Port Designs

Portal Design	Material Composition
 <p data-bbox="284 589 533 623">Hickman<sup>®</sup> Titanium Port</p>	Titanium and Silicone
 <p data-bbox="347 871 450 905">MRI<sup>®</sup> Port</p>	Thermo Plastic and Silicone
 <p data-bbox="336 1118 461 1152">Domé<sup>™</sup> Port</p>	Titanium and Silicone
 <p data-bbox="321 1443 481 1477">MRI<sup>®</sup> Dual Port</p>	Thermo Plastic and Silicone

**Procedure: Accessing the Port**

*Equipment:* Sterile gloves, mask, gauze pads, alcohol swabs, TSM dressing, injection caps, povidone-iodine swab sticks or CHG swabsticks, noncoring needle with clamping extension set, flush solutions 0.9% sodium chloride, heparin (100 U/mL), 5 mL syringes 10 mL, sharps container

- Verify physician order
- Educate patient on purpose of procedure and site observation after discontinuation
- Follow hand hygiene procedures
- Observe standard precautions
- Don gloves and mask
- Palpate site to locate septum
- Cleanse port access with alcohol, rotating in a circular motion from inside out; repeat two more times; let dry
- Cleanse access site with 2% CHG or povidone iodine, rotating in a circular motion from inside out; repeat two more times; let dry
- Remove and discard gloves
- Don second pair of sterile gloves
- Prepare noncoring needle by flushing device, with clamped extension tubing attached, with 10 mL preservative-free 0.9% sodium chloride injection
- Relocate port by palpation and immobilize device with nondominant hand
- Insert noncoring needle perpendicular to the septum, pushing firmly through skin and septum until needle tip contacts back of port
- Aspirate for blood return to confirm patency; flush with attached 10 mL sodium chloride
- Maintain positive pressure when removing syringe from port by engaging clamping device
- If port is to remain accessed:
  - Place sterile gauze under device wing to prevent rocking motion of needle
  - Anchor noncoring needle to skin using sterile tape
  - Cover needle and gauze with TSM dressing
  - Initiate prescribed therapy
- Document in patient record

## Deaccessing Implanted Port

To deaccess needle from port:

- Don gloves.
- Loosen the dressing covering the noncoring needle. Note discharge/drainage and discard in appropriate biohazard receptacle.
- Cleanse injection port with alcohol and attach 10-mL syringe containing sodium chloride.
- Vigorously irrigate the port using a pulsatile *push-pause* method.
- Withdrawing the noncoring needle requires a two-handed technique. With the nondominant hand, use your thumb and index finger to stabilize the port.
- Steadily, with an upward pull (perpendicular to the site), remove the needle with dominant hand. While withdrawing needle, activate the safety feature on the noncoring needle (Huber-Plus).
- If bleeding occurs at site, apply direct pressure using sterile gauze sponge.
- Apply dressing if needed.
- Document in patient record.

## Complications of CVADs

Complication	Signs & Symptoms	Treatment
<i>Insertion-Related</i>		
<b>Pneumothorax:</b> Collection of air in pleural space	Sudden chest pain, shortness of breath, dyspnea, crunching sound on auscultation, tachycardia, persistent cough, diaphoresis	Oxygen Chest tube may be necessary Monitor vital signs
<b>Hemothorax:</b> Blood enters pleural cavity	Sudden chest pain Dyspnea Tachycardia, hypotension, dusky skin color, diaphoresis, and hemoptysis	Remove the catheter and insertion needle and apply pressure to site Monitor vitals Oxygen Chest tube
<b>Chylothorax:</b> Chyle or lymph enters the pleural cavity due to transection of thoracic duct on left side	Same as hemothorax Milk-like substance drawn into the needle or catheter	Notify physician for catheter removal Oxygen Chest tube

## Complications of CVADs

Complication	Signs & Symptoms	Treatment
<b>Brachial plexus injury:</b> Nerves in upper dorsal spinal that supply arm, forearm, and hand	Tingling sensation in the fingers, pain shooting down the arm, or paralysis	Notify physician Pain medication Physical therapy
<b>Extravascular malposition</b>	Similar symptoms as pneumothorax or hemothorax	X-ray confirmation of catheter tip placement Removal of the catheter Oxygen Chest tube
<b>Intravascular malposition</b>	Tip into internal jugular rather than subclavian Noted when catheter is first used; difficulty in aspiration or infusion Discomfort or pain in shoulder, neck, or arm Ear gurgling sign	Not always removed Attempt to reposition if possible

*(Continued on the following page)*

## Complications of CVADs *(Continued)*

Complication	Signs & Symptoms	Treatment
<i>Post-Insertion Complications</i>		
<b>Air embolism:</b> Entry of air into the circulatory system	Chest pain, dyspnea, hypotension, lightheadedness, pallor, precordial churning murmur, thready pulse, unresponsiveness	Place patient in left lateral Trendelenburg position Clamp catheter Notify physician Prepare for resuscitation
<b>Dislodgment (Twiddler's syndrome)</b>	External portion of catheter is longer; catheter tip no longer positioned in SVC; exposed Dacron cuff; leaking of solution from catheter exit site; edema, burning sensation, or pain during infusion	X-ray confirmation of catheter placement May need to be removed Apply sterile dressing over site
<b>Catheter migration:</b> CVC moves from insertion placement site	Aspiration difficulties, burning sensation, discomfort or pain during infusion, edema of chest or neck, increased external catheter length; leaking around the insertion site, cardiac dysrhythmias, palpation of catheter in external jugular vein, patient complains of gurgling sound in ear	Radiographic verification of placement Assist with CVC removal or replacement

## Complications of CVADs

Complication	Signs & Symptoms	Treatment
<b>Catheter occlusion – Nonthrombolytic:</b> Crystallization of TPN; drug-drug or drug-solution incompatibilities	Sluggish flow rate, total occlusion, inability to flush or obtain blood withdrawal	Attempt to restore patency. See Troubleshooting Guide next section.
<b>Thrombolytic occlusions:</b> Deposits of fibrin and blood components within and around the CVC, intraluminal blood clot, fibrin sheath	Sluggish flow rates, total occlusion, inability to flush or obtain blood withdrawal; fibrin may be able to infuse solutions, but unable to aspirate blood “ball-valve effect”	Attempt to aspirate clot Initiate appropriate fibrinolytic treatment with t-PA; see Troubleshooting Guide next section

*(Continued on the following page)*

## Complications of CVADs *(Continued)*

Complication	Signs & Symptoms	Treatment
<p><b>External damaged catheter:</b> Break caused by scissors, penetration with needle; internal: rupture caused by use of smaller than 10-mL syringe formation that occludes the SVC</p>	<p><b>External:</b> Leakage from catheter, wet dressing, leakage at insertion site  <b>Internal:</b> Swelling in chest area, infusion of solution into chest wall; swelling at point of rupture</p>	<p><b>Internal:</b> Monitor for pin holes, leaks, wet dressing  <b>External:</b> Apply nonserrated clamp proximal to damaged part of catheter  <b>Internal:</b> Stop infusion; bed rest; prepare to repair or remove catheter</p>
<p><b>Site infection:</b> Includes exit site, pocket or tunnel infections</p>	<p>Cording of vein; site drainage, redness, tenderness, warmth; increase in basal temperature</p>	<p>Notify physician            Draw blood cultures from CVC            Obtain peripheral blood cultures            Administer antibiotics, anticoagulants            Evaluate CVC removal</p>



## Complications of CVADs

Complication	Signs & Symptoms	Treatment
<b>Superior vena cava syndrome:</b> Condition caused by blood clot, fibrin formation, that occludes the SVC	Progressive shortness of breath; cough; sensation of skin tightness; unilateral edema; cyanosis of face, neck, shoulder, and arms; jugular, temporal, and arm veins engorged; prominent venous pattern present over chest	Notify physician Radiographic confirmation of SVD syndrome Catheter may or may not be removed Anticoagulant therapy Place patient in semi-Fowler's position Oxygen Monitor fluid volume status

## Troubleshooting Guide for Occluded Central Catheters

Purpose of Catheter/ Agent Infused	Cause of Occlusion	Treatment
Prolonged use of catheter	Fibrin sheath or thrombosis	Thrombolytic: t-PA
Blood draw	Fibrin sheath or thrombosis	Thrombolytic: t-PA
Transfusion	Fibrin sheath or thrombosis	Thrombolytic: t-PA
Medication administration	Precipitate	NaHCO <sub>3</sub> or HCl
Cold medication or solution	Precipitate	NaHCO <sub>3</sub> or HCl
Stability (pH of medication)	Precipitate	NaHCO <sub>3</sub> or HCl
Medication with poor solubility (e.g., Dilantin)	Precipitate	NaHCO <sub>3</sub> or HCl
Time elapse since medication mixed	Precipitate	NaHCO <sub>3</sub> or HCl
Fat emulsions (or three-in-one TPN)	Lipid aggregation	Ethanol

HCl = hydrochloric acid

NaHCO<sub>3</sub> = sodium bicarbonate

## Care of CVC

### INS STANDARDS (2000) AND CDC (2002) STANDARDS

Catheter and Use	Flushing Maintenance	Administration Set Change	Site Care Dressing Change
<p>Percutaneous Intended for days to several weeks. Placement time: 7 days</p>	<p>Daily heparin flush 1:10 to 1:100 U heparin in volume equal to twice the volume of catheter plus any add-on devices</p>	<p>Replace sets and add-on devices every 72 hours Replace to administer blood products or lipid emulsions within 24 hours</p>	<p>Gauze every 2 days, TSM every 7 days Replace dressing when catheter is replaced; 2% chlorhexidine-based solution is preferred for cleansing site</p>
<p>Midline catheters In adults: replace every 72–96 hours Pediatric: do not replace unless clinically indicated</p>	<p>Daily heparin flush with 1:10 to 1:100 U heparin in volume equal to twice the volume of catheter plus any add-on devices</p>	<p>Replace tubing and add-on devices every 72 hours Replace to administer blood or lipids within 24 hours</p>	<p>Replace dressing when the catheter is removed or dressing integrity compromised Visualize site daily</p>

*(Continued on the following page)*

## Care of CVC (Continued)

### INS STANDARDS (2000) AND CDC (2002) STANDARDS

<b>Catheter and Use</b>	<b>Flushing Maintenance</b>	<b>Administration Set Change</b>	<b>Site Care Dressing Change</b>
CVC including PICC and hemodialysis catheters	With open-ended valves: 1:10 or 1:100 U heparin in volume equal to twice the volume capacity of catheter plus any add-on devices; daily to weekly  With closed-end catheters (Groshong or PASV) tip: use 10–20 mL of 0.9% sodium chloride weekly	Replace tubing and add-on devices every 72 hours Replace tubing used to administer blood or lipid emulsions within 24 hours	Replace gauze dressings every 2 days, TSM every 7 days Tunneled catheters that are well healed may not need dressing

## Care of CVC

### INS STANDARDS (2000) AND CDC (2002) STANDARDS

Catheter and Use	Flushing Maintenance	Administration Set Change	Site Care Dressing Change
Implanted ports: use long-term (years)	1:10 or 1:100 U heparin in volume equal to twice the volume of catheter and any add-on devices. If not being used, flush every 4 weeks.	Replace tubing and add-on devices every 72 hours. Replace tubing used to administer blood or lipid emulsions within 24 hours.	Replace gauze every 2 days, TSM every 7 days. No dressing is needed after incision is healed. Change no-coring needle at least weekly.

Use lowest heparin dose to maintain patency  
 Use single-use flushing systems if available  
 Use 10-mL syringe for all flushing procedures  
 Use pulsatile *push-pause* method to flush

## Notes

**Contents: BLOOD**

ABO Blood Grouping Chart	106
ABO Compatibilities for Packed Red Blood Cell (RBC) Components	106
Donor Blood Testing	106
Blood Preservatives	107
Blood Donor Collection Methods	107
Equipment: Blood Administration	108
Summary of Blood Components	110
Procedure: Administration of Blood Components	114
Risks of Transfusion Therapy	116
Summary of Common Transfusion Reactions	117

## ABO Blood Grouping Chart

Blood Grouping	Recipient Antigens on RBC	Antibodies Present in Plasma
A	A	Anti-B
B	B	Anti-A
AB	A and B	None
O	None	Anti-A and Anti-B

## ABO Compatibilities for Packed Red Blood Cell (RBC) Components

Recipient Blood Type	Donor Unit, First Choice	Donor Unit, Second Choice
A+	A+	O, A+
B+	B+	O-, B+
AB+	AB+	O-, A+, B+, AB+
O+	O+	O+
A-	A-	O-, A-
B-	B-	O-, B-
AB-	AB-	O-, A-, B-, AB-
O-	O-	O-

**Note:** The universal RBC donor is O-negative; the universal recipient is AB-positive.

## Donor Blood Testing

### Key Points

- The ABO group must be determined by testing the RBCs with anti-A and anti-B sera.
- The Rh type must be determined with anti-D serum. Units that are D-positive must be labeled as Rh-positive.



- All donor blood must be tested to detect transmissible disease.
- Screening tests include:
  - Hepatitis B surface antigen (HBsHg)
  - Hepatitis B core antibody (anti-HBc)
  - Hepatitis C virus antibody (anti-HCV)
  - HIV-1 and HIV-2 antibody (anti-HIV-1 and HTLV-II)
  - HIV p 24 antigen
  - HTLV-I and HTLV-II antibody (anti-HTLV-I and HTLV-II)
  - Serologic test for syphilis
  - Nucleic acid amplification testing (NAT)
  - NAT for West Nile Virus (WNV)

### Blood Preservatives

#### **CPDA-1: Citrate phosphate dextrose adenine; shelf life 35 days**

Contains adenine, which helps RBCs synthesize adenosine triphosphate (ATP) during storage

#### **CP2D: Citrate phosphate dextrose dextrose; shelf life 35 days**

#### **AS: Sodium chloride dextrose adenine; shelf life 42 days**

AS-1: Adsol®, AS-3 Nutrice, and AS-5 Opitsol

Combination of saline or mannitol. RBCs with these additives have a better flow rate.

### Blood Donor Collection Methods

#### **Homologous**

Transfusion of any blood component that was donated by someone other than the recipient

#### **Autologous**

Collection, storage, and delivery of a recipient's own blood

#### **Types**

#### **Predeposit or Preoperative Autologous Blood Donation**

Predeposit is collection and storage of the recipient's own blood for reinfusion during or after a later operation

**Typical Uses**

Hip or knee replacement surgery  
Elective cardiac surgery  
Spinal fusion  
Elective major vascular surgery  
Heart-lung transplant

**Contraindications**

Hemoglobin less than 11 g/dL  
Bacterial infection  
Severe aortic stenosis  
Unstable angina  
Severe left main coronary artery disease

**Intraoperative Blood Salvage****Typical Use**

Surgical procedure with anticipated blood loss  
Patient unable to donate preoperatively

**Contraindications**

Malignancy at operative site  
Bacterial contamination at operative site  
Use of microfibrillar collagen materials  
Postoperative salvage

**Designated/Directed**

Donation of blood from selected friends or relatives of the patient  
Designated donors have the same screening as homologous donation  
The unit must be compatible with that of the intended recipient

**Equipment: Blood Administration**

**Follow institutional protocol (policies/procedures) for equipment.**

**General Recommendations**

**Catheter:** 18 g or larger catheter to provide adequate flow rates. A 20-g thin-walled catheter may be used for limited transfusions.

**Solution:** 0.9% sodium chloride is the only acceptable solution to be used with blood products.

**Administration sets:** Blood administration sets available in two-lead Y-type tubing or single-lead tubing. The sets come with an inline filter (170 micron) designed to remove debris in stored blood.

**Filters:** 170-micron filter used for blood administration.

Minimum time for a blood filter is 4 hours.

*Microaggregate filters:* Added to standard blood administration set. Designed to remove 20–80 micron particles, filtering out the microaggregates that develop in stored blood.

*Leukocyte depletion filters:* HLA immunization is directly linked to the number of leukocytes present in blood products. These filters remove 99.9% of leukocytes present in the unit.

**Blood warmer:** Temperature device specifically designed to warm blood. Most transfusions do not require use of blood warmers. Adhere to manufacturer guidelines when using specific warmer. Blood warmer is most often used for rapid or massive transfusions, in neonatal exchange transfusion, and for a patient with potent cold agglutinins. **DO NOT USE HOT WATER BATH OR MICROWAVE!**

**Electronic monitoring devices:** Only pumps designed for infusion of whole blood or RBCs may be used. Check with manufacturer.

*Pressure bag:* Used to increase flow rates during transfusion, usually emergencies.

## Summary of Blood Components

Blood Component	Volume	Action/Use	Infusion Guide	Special Considerations
<i>RBCs</i>	250–350 mL	Improves oxygen-carrying capacity Symptomatic anemia, bone marrow failure	0.9% NaCl primer; transfuse in 4 hours; use 170-micron filter Y set; recommend leukocyte reduction filter	AB- and Rh-compatible; 1 U raises the Hgb 1 g and Hct 3%–4%
<i>Platelets: random donor</i>	50–70 mL/U Usual dose: 6–10 U	Control or prevent bleeding associated with platelet deficiencies	Administer rapidly: 1 U/10 min Use blood filter, syringe push, or standard Y set	1 U increases platelet count by 5000 Infuse individually or may be pooled; ABO/Rh preferred
<i>Fresh frozen plasma FFP</i>	200–250 mL	Replacement of clotting factors; not used for volume expansion	Storage: 18°C for 1 yr Standard blood filter; may be infused 20 mL over 3 min or more slowly within 4 hours	Does not provide platelets 1 U raises the level of clotting factor 2%–3% Must be ABO-compatible

## Summary of Blood Components

Blood Component	Volume	Action/Use	Infusion Guide	Special Considerations
<i>Cryoprecipitate</i>	5–10 mL/U; usual order is for 6–10 U	Each unit contains factor VIII and factor XI; controls bleeding in coagulation disorders. Use to treat hemophilia A; hypofib- rinogenemia; factor VIII deficiency, DIC	Standard Y filter	ABO-compatible. Infuse within 6 hours from thawing; saline may be added to bag to facilitate recovery of product

(Continued on the following page)

**Summary of Blood Components** *(Continued)*

<b>Blood Component</b>	<b>Volume</b>	<b>Action/Use</b>	<b>Infusion Guide</b>	<b>Special Considerations</b>
<p><i>Albumin</i>                      5% = 12.5g/                      250 mL                      25% = 12.5g/                      50 mL</p>	<p>5% in 250–500 mL: isotonic                      25% in 50–100 mL: hypertonic</p>	<p>Plasma volume expander; used for hypovolemic shock, support blood pressure; induces diuresis in fluid overload</p>	<p>Rate 2–4 mL/min for 5% solution; 1 mL/min for 25% solution                      Supplied in glass bottles</p>	<p>25%—hypertonic and is 5× more concentrated than 5%                      Give with extreme caution—can cause circulatory overload                      No type and cross                      Store at room temperature</p>

## Summary of Blood Components

<b>Blood Component</b>	<b>Volume</b>	<b>Action/Use</b>	<b>Infusion Guide</b>	<b>Special Considerations</b>
<i>Plasma protein fraction</i>	Glass bottle with tubing: 250 mL	Same as for albumin	Equivalent to 5% albumin	Has fewer purification steps than albumin; no type and cross. High sodium content
<i>Immune serum globulin (ISG)</i>	See guidelines for nonspecific ISG preparations	Treatment of AIDS to supply passive immune protection	Use filter needle to draw up; use filter for drip	Nonspecific: Gammimune N, Gammogard, Gammar-IV, IGIV, Iveegam, Sandoglobulin, Venoglobulin-1, and Venoglobulin-S

**Procedure: Administration of Blood Components**

**Verify physician order:** Order is required. Patient needs to sign informed consent.

**Type and cross-matching:** ABO and Rh typing accomplished in blood banking department. Each unit transfused must be typed and crossed with individual paperwork.

**Select equipment:** Refer to equipment list. Ensure a patent IV prior to obtaining blood from bank: #18-g catheter is ideal; use blood administration set for most transfusions with 170-micron filter; use 0.9% sodium chloride as primer. Addition of extra filter requires a physician's order.

**Prepare patient:** Patient education regarding the procedure: explain need for blood, the procedure, and related concerns. Assessment of patient includes baseline vitals, evaluation of kidney function, and respiratory assessment. Premedicate if ordered (diuretics, antihistamines, or antipyretics). Document education in chart. Make sure IV catheter is patent or start new line using #18-g catheter, handY administration set with 0.9% sodium chloride.

**Obtain blood from blood bank:** Obtain blood when notification of type and cross completed. Blood cannot be returned to the bank after 30 minutes. Make sure ready to handle blood once obtained. Blood stored in special refrigerator 1–6°C. Blood may not be stored in refrigerators on the unit. Sign out blood checking:

Donor number

ABO and Rh type

Check color, appearance, and expiration date of component

Patient name on unit



**Procedure: Administration of Blood Components****Preparing for administration:**

Upon return to unit, check blood component with another qualified nurse. Checking:

Patient name on unit to armband

ABO and Rh

Donor unit number

Color, appearance, and expiration date of component

Component to be administered

Establish baseline vitals; record on flow sheet

**Initiating the transfusion:**

All blood must be infused within 4 hours

Handle blood wearing gloves

Make sure Y set is primed so saline covers filter

Begin transfusion slowly, turning off saline

Monitor patient

Stay with patient for the first 5–15 minutes of transfusion

Monitor vitals and record following institution policy

*Note:* No medications can be added to blood!

**Discontinuing transfusion:**

Once completed: dispose of administration set; empty transfusion bag in biohazard container; note time completed on flow sheet and transfusion record

Document time of transfusion, volume given, patient's condition, and tolerance to transfusion

## Risks of Transfusion Therapy

Viral Infection	Estimated Risks per Unit
HIV-1 and HIV-2	1:1,900,000
HTLV-1 and HTLV-2	1:641,000
HAV	1:1,000,000
HBV	1:63,000
HCV	1:1,600,000
Parvovirus B19	1:40,000
<b>Parasitic Infections</b>	
Babesia and malaria	1:1,000,000
<b>Noninfectious Risks</b>	
Fatal hemolytic transfusion reaction	1:1,300,000
Febrile nonhemolytic transfusion reaction	1%
Minor allergic reaction	1%
Anaphylaxis	1/20,000
<b>Noncardiogenic Pulmonary</b>	
Edema/transfusion-related acute lung injury	1/5,000

## Summary of Common Transfusion Reactions

Transfusion Reaction	Signs & Symptoms	Interventions	Prevention
<i>Immune Reaction</i>			
<i>Acute Hemolytic Transfusion Reaction</i>	Burning sensation along vein; lumbar pain, flushing of face and chest, bleeding, tachycardia, tachypnea, hemoglobinemia, hemoglobinuria, shock, vascular collapse, death	<b>STOP THE TRANSFUSION!</b> Get help immediately Treat shock Maintain BP with colloidal solutions Administer diuretics to maintain blood flow	Extreme care during entire identification process. Strict attention to cross-matching protocols. Start transfusion slowly and monitor for first 5–15 minutes.
<i>Delayed Hemolytic Reaction</i>	Decreased hematocrit and hemoglobin levels; fever (continual, low-grade); jaundice (mild); malaise Indirect hyperbilirubinemia	No acute treatment required; monitor hematocrit level, renal function; coagulation profile Notify physician and transfusion services	Strict attention to cross-matching protocols

*(Continued on the following page)*

## Summary of Common Transfusion Reactions (Continued)

Transfusion Reaction	Signs & Symptoms	Interventions	Prevention
<i>Nonhemolytic Reactions</i>			
<i>Febrile Reaction</i>	Fever, rise in temperature of 1°F in association with transfusion Chills, headache, nausea, vomiting, chest pain, nonproductive cough, malaise	Stop transfusion, and start normal saline. Notify physician. Monitor vitals. Anticipate order for antipyretic agents. If ordered, restart transfusion slowly.	Use leukocyte-reduced blood component, filter

## Summary of Common Transfusion Reactions

Transfusion Reaction	Signs & Symptoms	Interventions	Prevention
<i>Allergic Reaction</i>	Itching, hives, rash, urticaria, facial flushing, runny eyes, anxiety, dyspnea, wheezing	Stop transfusion. Keep vein open with normal saline. Notify physician. Monitor vitals. Anticipate antihistamine order. If ordered, restart transfusion slowly. Mild reaction can precede severe allergic reaction—monitor.	If known, mild allergic reaction may occur with blood transfusion; may receive diphenhydramine (Benadryl) before transfusion.
<i>Allergic Anaphylaxis</i>	Anxiety, urticaria, wheezing, hypotension, GI distress, shock, cardiac distress—death	Stop transfusion. Keep vein open with normal saline. CPR if necessary. Anticipate order for steroids. Maintain BP.	Use autologous blood. Use blood from donors who are IgA-deficient or by administering only well-washed RBCs in which all plasma has been extracted.

*(Continued on the following page)*

### Summary of Common Transfusion Reactions *(Continued)*

<b>Transfusion Reaction</b>	<b>Signs &amp; Symptoms</b>	<b>Interventions</b>	<b>Prevention</b>
<i>Graft-Versus-Host Disease (GVHD)</i>	Diarrhea, fever, rash, hepatitis, bone marrow suppression, overwhelming infection	No effective therapy; treat symptoms Morbidity rate high	Irradiation of blood products used in immunocompromised patients; use leukocyte-reducing filter
<i>Non-Immune Reactions</i>			
<i>Circulatory Overload</i>	Hypervolemia, headache, dyspnea, constriction of chest, coughing, cyanosis	Stop transfusion. Elevate head of bed. Notify physician. Rapid-acting diuretics, oxygen, therapeutic phlebotomy may be indicated.	Frequent monitoring of patient Administration of components slowly

### Summary of Common Transfusion Reactions

Transfusion Reaction	Signs & Symptoms	Interventions	Prevention
<i>Coagulation Imbalances</i>	Abnormal bleeding from surgical sites, IV site, or breaks in skin	Monitor laboratory reports Coagulation studies Platelet counts, protect from injury Anticipate platelet administration	Administration of fresh blood less than 1 week old
<i>Potassium Toxicity</i>	Elevated potassium levels, slow irregular heart rate, nausea, muscle weakness, ECG changes, diarrhea, renal failure	Stop or slow transfusion. Monitor ECG, notify physician, remove excess potassium: concurrent administration of hypertonic dextrose and insulin or administer polystyrene sulfonate orally or by enema	In patient receiving multiple transfusions: use only the freshest blood; potassium level in blood rises as blood ages

(Continued on the following page)

### Summary of Common Transfusion Reactions *(Continued)*

Transfusion Reaction	Signs & Symptoms	Interventions	Prevention
<i>Hypothermia</i>	Drop in core temperature, chills, peripheral vasoconstriction, ventricular arrhythmias, cardiac arrest	Monitor patient. Use external warming techniques (blankets, lights)	Use blood warmers if possible. Warm blood to 37°C
<i>Citrate Toxicity</i>	Hypocalcemia-induced cardiac dysrhythmias Tingling of fingers, muscle cramps, confusion, hypotension, cardiac arrest	Slow rate of infusion. Administer calcium chloride or calcium gluconate. Do not add calcium to infusion blood.	Administer fresh blood. Monitor calcium levels during pre/post transfusion, monitor patients with liver impairment closer for hypocalcemia.



### Summary of Common Transfusion Reactions

Transfusion Reaction	Signs & Symptoms	Interventions	Prevention
<i>Non-Immune Infection Related</i>			
<i>Hepatitis B and C</i>	Elevated liver enzymes, fever, jaundice, malaise, nausea, pharyngitis, dark urine	No specific treatment—nursing care revolves around symptomatic treatment	Hepatitis B vaccine. Pretransfusion testing of donor blood. No vaccine for hepatitis C
<i>HIV-1</i>	6 stages by Walter Reed Classification System. Positive HIV flu-like syndrome to total anergy with chronic fungal and viral infections	No cure; treatment is symptomatic	Donor screening. New NAT test
<i>Cytomegalovirus (CMV)</i>	Systemic CMV: pneumonia, hepatitis, and retinitis	No specific treatment	Reduce CMV exposure in specific patient populations; use blood from CMV seronegative donors or depleted leukocytes

## Notes

**Contents: NUTRI SUPPORT**

Components of a Nutritional Assessment	126
Types of Malnutrition	127
Dextrose Solutions for Total Parenteral Nutrition	128
Protein (Amino Acids) for Total Parenteral Nutrition	128
Examples of Amino Acid Solutions	128
Lipid Administration for Total Parenteral Nutrition	129
Modalities for Delivery of Nutritional Support	130
General Guidelines for Administration of Nutritional Support	131
Peripheral Parenteral Nutrition (PPN)	132
Total Parenteral Nutrition (TPN)	132
Total Nutrient Admixtures (TNAs)	133
Cyclic Therapy (C-TPN)	134
Specialized Parenteral Formulas	135
Common Complications Associated with Nutritional Support	136

## Components of a Nutritional Assessment

### History

- Medical
- Social
- Dietary

### Anthropometric Measurements

- Skinfolds
- Height and weight
- Midarm circumference
- Midarm muscle circumference

### Biochemical Assessment

- Serum albumin and transferrin levels
- Serum electrolytes
- Total lymphocyte count
- Urine assays (creatinine, height index)

### Energy Requirements

### Physical Examination

### Other Indices

- Nitrogen balance
- Indirect calorimetry
- Prognostic nutritional Index (PNI)

### CALCULATIONS

Calculation of current weight as % of the usual weight:

$$\% \text{ Ideal Body Weight (IBW)} = [\text{Current weight/IBW}] \times 100$$

Recent change in body weight calculation

$$\% \text{ of Usual Body Weight (UBW)} = [\text{Current body weight/UBW}] \times 100$$

Total Lymphocyte Count (TLC) calculation (used for immunocompromised clients)

$$\text{TLC} = \frac{\% \text{ lymph} \times \text{WBC}}{100}$$

A loss of 10% of the usual weight or a current weight less than 90% of IBW is considered to be a risk factor of nutrition-related complications.

Mild malnutrition = 85–95% IBW

Moderate malnutrition = 75–84% IBW

Severe malnutrition = less than 75% IBW

Note: In simple starvation 20% loss of body weight is associated with marked decreases in muscle tissue and subcutaneous fat.

## Types of Malnutrition

### **MARASMUS**

Decrease in the intake of calories with adequate protein-calorie ratio. Gradual wasting of body fat and skeletal muscle, with preservation of visceral proteins. Looks emaciated; decreased anthropometric measurements and energy. Associated with chronic illness and starvation.

### **KWASHIORKOR**

Characterized by an adequate intake of calories along with a poor protein intake. Causes visceral protein wasting and preservation of fat and somatic muscle. Associated with liquid diets, fat diets, and long-term use of IV fluids containing dextrose. May appear obese and have adequate anthropometric measurements—depressed immune function.

### **MIXED MALNUTRITION**

Characterized by aspects of marasmus and kwashiorkor. Associated with depleted fat stores, immune incompetence, and acute catabolic stress. Associated with highest risk of morbidity and mortality.

**Dextrose Solutions for Total Parenteral Nutrition**

<b>SOLUTION %</b>	<b>g/L</b>	<b>kcal/L</b>	<b>mOsm/L</b>
5	50	170	252
10	100	340	505
20	200	680	1010
30	300	1020	1515
40	400	1360	2020
50	500	1700	2525
60	600	2040	3030
70	700	2380	3535

*Note:* Dextrose increases the metabolic rate, which raises ventilatory requirements.

*Note:* A 10% solution is the highest percentage that can safely be infused into a peripheral vein.

*Note:* Solutions of 20% and above must be infused into a central vein.

**Protein (Amino Acids) for Total Parenteral Nutrition**

Protein requirements for healthy adults: 0.8% g/kg/d

In critical illness state: 1.2–2.5 g/kg/d

**Examples of Amino Acid Solutions**

<b>Protein Solution</b>	<b>Concentration (%)</b>	<b>Nitrogen (%)</b>	<b>Osmolarity (mOsm/L)</b>
Aminosyn	3.5	0.55	357
Aminosyn II	4.25	0.65	438
Stress formula (Aminosyn-HBC)	7	1.12	665
Travasol	5.5	0.924	575
Novamine	15	2.37	1388
FreAmine III	3	0.46	300
HepatAmine	8	1.2	785

## Lipid Administration for Total Parenteral Nutrition

*Note:* 1g fat = 9 kcal

Use of fat can help control hyperglycemia in stress states

Emulsion (%)	Available	Osmolarity (mOsm/L)
Liposyn II 10%	50/50 safflower oil, soybean oil	1.1 kcal/mL - 276
Liposyn III 20%	Soybean oil	2.0 kcal/mL - 292
Intralipid 10%	Soybean oil	1.1 kcal/mL - 280
Nutrilipid 10%	Soybean oil	1.0 kcal/mL - 280
Nutrilipid 20%	Soybean oil	2.0 kcal/mL - 330

\*30% emulsions are available but are not to be given by direct IV infusion; used in combination with dextrose solutions and amino acids so total fat content does not exceed 20%.

### Rate of Administration

May be administered via injection port on administration set near infusion site.


10% - 0.1 mL/min for first 10–15 min. Rate to administer 500 mL over 4–6 hr.

20% - 0.5mL/min for first 15–20 min. Administer 1 g/kg of body weight over 4 hr

*Note:* An infusion pump is recommended; a 1.2-micron filter must be used with lipids

## Modalities for Delivery of Nutritional Support

Algorithm for determining the choice of nutritional support





## General Guidelines for Administration of Nutritional Support

1. One catheter lumen should be designated for nutritional support only; it should be labeled "Nutritional Support Only."
2. The container of nutritional support must not infuse beyond a 24-hour period of time. If the next solution container is not ready, a 10% dextrose solution must be hung to prevent rebound hypoglycemia.
3. Refrigerated nutritional support admixtures should be removed from the refrigerator 1 hour prior to administration.
4. When initiating TPN the infusion is to be introduced at a relatively slow rate (50 mL/hr) to prevent hyperglycemia.
5. The infusion MUST be maintained at the prescribed rate. If it should get behind, do not "catch up." The infusion may be adjusted with no more than a 10% margin (up or down) of the original rate.
6. Nutritional support should be administered using an electronic infusion pump.
7. The flow rate should be monitored at intervals of 30–60 minutes even if an EID is used.
8. Vital signs should be monitored every 4 hours, including temperature.
9. The patient's weight should be monitored with serial weights daily.
10. Strict intake and output should be monitored.
11. A chemistry panel should be drawn every 3 days initially when starting TPN.
12. Adequate oral or enteral intake must be assessed prior to discontinuing TPN.
13. Patients must be weaned off nutritional support to prevent rebound hypoglycemia. This is done over 24–48 hours by gradually decreasing the volume of TPN while monitoring patient response.
14. Use a 0.2-micron filter when administering parenteral nutrition of dextrose and amino acids. Use a 1.2-micron filter with lipid emulsions.

## Peripheral Parenteral Nutrition (PPN)

### Key Points

- Nutritional support delivered via peripheral vein
- Used to nourish patients who are either already malnourished or who have potential for developing malnutrition
- Considered “nitrogen-sparing” therapy
- Usually used for up to 2 weeks in selected patients who cannot ingest or absorb oral or enteral tube-delivered nutrients
- Provides dextrose in 10% solution and amino acids 1.75–3.5%
- Fat emulsions can be given via a peripheral line

### Advantages

- Avoids insertion and maintenance of central catheter
- Delivers less hypertonic solution than central venous TPN
- Reduces chance of metabolic complications
- Increases calorie source

### Disadvantages

- Cannot be used in nutritionally depleted patients
- Cannot be used in volume-restricted patients
- Does not usually increase a patient’s weight
- May cause phlebitis

### Monitoring

- Follow general guidelines

## Total Parenteral Nutrition (TPN)

### Key Points

- TPN is provided via central line due to hyperosmolarity (1800–3000 mOsm/L) of the solutions
- TPN is administered at rates not to exceed 200 mL/hr
- Dextrose 20%–70% is administered as a calorie source
- Used for prolonged periods in malnutrition states: months to years

- Reverses starvation and achieves tissue synthesis, repair, and growth
- All TPN solutions must be filtered; a 0.2-micron filter is used for dextrose and amino acid solutions; a 1.2-micron filter must be used with lipids
- Must have a dedicated lumen

### **Advantages**

- For long-term use
- Useful in patient with large caloric and nutrient needs
- Provides calories, restores nitrogen balance, and replaces essential vitamins, electrolytes, and minerals
- Promotes tissue synthesis, wound healing, and normal metabolic function
- Allows bowel rest and healing
- Is nutritionally complete

### **Disadvantages**

- May require a minor surgical procedure to insert catheter or port
- May cause metabolic complications
- Fat emulsions may not be used effectively in a severely stressed patient
- Risk of pneumothorax or hemothorax

### **Monitoring**

- Follow general guidelines

## **Total Nutrient Admixtures (TNAs)**

### **Key Points**

- TNAs are solutions that have combinations of dextrose, amino acids, and fat emulsion in one container
- Referred to as “3-in-1” or “all-in-one”
- Provide 3-L container that infuses over 24 hours
- Used frequently in home care settings

- TNA **must** use a 1.2-micron filter
- Risk of cholestasis and that long-chain triglycerides may depress the immune system
- Catheter occlusions resulting from fat deposits have been reported
- Bacterial or fungal growth may be enhanced by TNA solutions

### Monitoring

- See general guidelines

## Cyclic Therapy (C-TPN)

### Key Points

- Delivers concurrent dextrose, amino acids, and fat over a regimen of a reduced period—usually 12–18 hours
- Indicated for patients stabilized on continuous TPN
- Used for long-term parenteral nutrition
- Patient's cardiovascular status must be able to accommodate fluid volume during cyclic phase
- For patients without complaints such as glucose intolerance or precarious fluid balance, a 12-hour cycling regimen can be used
- A patient who is septic or metabolically stressed is not a good candidate for C-TPN
- Improves quality of life by encouraging normal daytime activities
- Observe for symptoms of hypoglycemia, hyperglycemia, dehydration and excessive fluid, and sepsis associated with central line
- Hyperglycemia can occur during peak C-TPN flow rate.
- Check blood sugar 1 hour after tapering off C-TPN daily until stable.

### Monitoring

- See general guidelines

## Specialized Parenteral Formulas

### RENAL FORMULAS

#### Key Points

- For patients in renal failure who are in need of TPN
- Minimal quantities of essential amino acids
- Do not contain nonessential amino acids
- Standard crystalline amino acid solutions contain essential and nonessential amino acids
- Decrease rate of blood urea nitrogen formation and minimize deterioration of serum potassium, magnesium, and phosphorus
- Common preparations: Aminess 5.2%; Aminosyn-RF 5.2%; NephroAmine

### HEPATIC FORMULAS

#### Key Points

- Solutions high in branched-chain amino acids (BCAA) are designed for patients with liver disease
- Formulas are limited to patients with encephalopathy
- Common preparations: BranchAmin, HepatoAmine, Novamine
- Contraindicated in patients who are anuric

### STRESS FORMULAS

#### Key Points

- Used for patients with infections, sepsis, and trauma of burns, surgery, shock, and blunt or penetrating injuries
- Severely stressed patient needs more protein to meet increased nutritional needs—high metabolic stress formulas are needed; increase in nitrogen excretion caused by altered protein metabolism—occurs in stressed patients
- Formulas with high BCAA replenish those depleted in the stressed patient
- Examples of stress formulas: Aminosyn-HBC, BranchAmin, FreAmine HBC, Novamine

## Common Complications Associated with Nutritional Support

Complication	Symptoms	Treatment	Prevention
<i>Air Embolism</i>	Cyanosis, tachypnea, hypotension, churning heart murmur, shock	Immediately place patient on left side and lower the head of bed; oxygen; call for assistance; prepare for resuscitation	Line placement by appropriately trained personnel; use care in injection cap changes; use Luer locks; no scissors near catheter
<i>Vein Thrombosis</i>	Swelling or pain in one or both arms, shoulders, or neck; increased anterior chest venous pattern	Diagnosis made by arm venography, contrast studies, MRI Treatment—extent of thrombus Conservative treatment—anticoagulants	Tip placement in SVC, not upper arm or subclavian Early recognition of symptoms
<i>Catheter Malposition</i>	Swelling of arm, neck, or pain; difficulty flushing catheter; patient complains of ear gurgling	Reposition with guidewire Reposition patient before flushing line	Not always possible to prevent Follow techniques to prevent malposition

## Common Complications Associated with Nutritional Support

Complication	Symptoms	Treatment	Prevention
<i>Altered Glucose Metabolism—Hypoglycemia: Rebound</i>	Diaphoresis, irritability, nervousness, shaking, decreased serum glucose	Administer dextrose or decrease insulin	Maintain IV at constant rate; wean gradually Monitor blood sugars q 6 hr
<i>Hyperglycemia</i>	Increased serum glucose, acetone breath, anxiety, confusion, dehydration, polydipsia, polyuria, malaise	Decrease dextrose TPN concentration or decrease rate of administration of insulin per sliding scale	Accurate glucose monitoring, gradual TPN rate increases
<i>Hypokalemia</i>	Serum K <sup>+</sup> below 3.5 mEq/L, anorexia, fatigue, muscle weakness, decreased gastric motility, ECG changes	TPN supplementation; replace GI losses	Monitor serum potassium, strict I and O, assess for digitalis toxicity

*(Continued on the following page)*

**Common Complications Associated with Nutritional Support** *(Continued)*

<b>Complication</b>	<b>Symptoms</b>	<b>Treatment</b>	<b>Prevention</b>
<i>Sepsis</i>	Chills, fever, malaise, elevated WBC count, diarrhea, tachycardia, tachypnea, flushing, hypotension	Remove catheter or replace catheter over guidewire Antibiotics Administer oxygen Prepare to treat septic shock	Maintain aseptic technique Aseptic dressing changes Use 0.22-micron filter
<i>Refeeding Syndrome</i> <i>Occurs during initial phase of TPN; causes an electrolyte shift</i>	Cardiorespiratory complications, edema, hypernatremia, hypokalemia, hypomagnesemia, hypophosphatemia	Once body has reestablished normal albumin and electrolyte balance, the refeeding processes are reversed	Averted by starting TPN slowly and gradually increasing rate. Monitor patient response to TPN



## Common Complications Associated with Nutritional Support

Complication	Symptoms	Treatment	Prevention
<i>Essential Fatty Acid Deficiency</i>	Minimal symptomatology until long-term soft-tissue calcification, hypocalcemia, tetany (numbness and tingling of mouth and fingers) Increased BUN, alopecia, cracked skin with dermatitis	Fat emulsion supplementation in TPN	Accurate calculation of protein and fat and CHO ratios to maintain positive nitrogen balance

Notes


**Contents: MEDICATION ADMINISTRATION**

Intermittent Infusion—Piggyback Through Primary Pathway	142
Direct IV Push Medications	143
Medication Delivery Through Volume Control Chamber	143
Subcutaneous Medication Administration	145
Intraosseous Medication Administration	145
Epidural Medication (Catheters and Ports)	146
Monitoring Epidural Medication Administration	147
Intrathecal Medication Administration	147
Intraperitoneal (IP) Medication Administration	148

## Intermittent Infusion – Piggyback Through Primary Pathway

### Key Points

- The secondary infusion (piggyback) must be higher than the primary infusion bag
- Use extension hook supplied in secondary administration set
- Adjust secondary infusion rate
- Once secondary infusion is completed, primary solution will start to drip again



## Direct IV Push Medications

### Key Points

- Check compatibility of drug with primary solution
- Dilute opioid narcotics; follow recommendation of manufacturer
- Use separate syringe for each drug administered; select syringe size large enough to accommodate volume of medication and aspirate-procedure to confirm VAD patency
- Wear gloves
- Swab lowest medication injection port with alcohol
- Insert needleless syringe
- Aspirate to check for blood return
- Slowly administer medication over **1 minute** minimum
- Flush with sodium chloride if appropriate

### Advantages

- Barriers of drug absorption are bypassed
- Drug response is rapid and usually predictable
- Patient is closely monitored during full administration of medication

### Disadvantages

- Adverse effects occur at the same time and rate as therapeutic effects
- The IV push method has the greatest risk of adverse effects and toxicity because serum drug concentrations are sharply elevated
- Speed shock is possible from too-rapid administration of medication

## Medication Delivery Through Volume Control Chamber

### Key Points

- Used most frequently with pediatric clients
- Medication is added to the volume control chamber and diluted with IV solutions


- Infusion is generally over 15 minutes to 1 hour, or adjusted continuous
- Chamber must be labeled

**Advantages**

- Runaway infusions avoided
- Volume of fluid in which the drug is diluted can be adjusted

**Disadvantages**

- Medication must travel the length of the tubing
- A portion of the medication can be left in the tubing after the chamber empties
- Incompatibilities may occur



## Subcutaneous Medication Administration

### Key Points

- Select insertion site with adequate subcutaneous tissue: a fat fold of at least 1 inch (supraclavicular, anterior chest wall, lower abdomen, outer aspects of arms and thighs)
- Avoid areas that are scarred, infected, irritated, edematous, bony, or highly vascularized
- Used for delivery of pain medication
- Use 25–27 g, 1/2-inch catheter
- Rotate access site every 3–5 days
- Wear gloves

### Advantages

- Easy care for home management of pain
- Decreases the number of times tissue is traumatized by repeated injections
- Better home management of pain
- Decrease in pain breakthrough

### Disadvantages

- Local irritation at site
- Route inappropriate for volume larger than 1 mL/hr

## Intraosseous Medication Administration

### Key Points

- Alternative for infusion of fluids and drugs in infants and children up to 6 years of age
- Use of vascular network of the long bones—medullary cavity
- Use intraosseous needle; must be removed with 24 hours
- Use this route only in emergency
- Once needle removed, sterile gauze pressure dressing should be applied; inspect daily and redress for 48 hours

### Advantages

- Provides quick access in emergency cases for fluid and drug administration

**Disadvantages**

- Potential for osteomyelitis, cellulitis
- Potential damage to the epiphyseal plate

*Refer to Chapter 11 in Phillips, L. Manual of IV Therapeutics, 4th ed., F.A. Davis Co., 2005, for more information on intraosseous medication and fluid administration.*

**Epidural Medication (Catheters and Ports)****Key Points**

- Placement of epidural catheter or port is a medical act
- Epidural space surrounds the spinal cord
- Used for pain management
- Use as single-bolus injection or continuous infusion
- Medications that can be administered by epidural route include:
  - Preservative-free Astromorph or Duramorph
  - Sublimaze (Fentanyl)
  - Bupivacain (Marcain)
- Avoid preservatives (alcohol, phenol, sodium metabisulfite) in medications—can damage the neural tissue
- After insertion, lay the exposed catheter length cephalad along the spine and over the shoulder
- Use a 0.22-micron inline filter to prevent particulate matter from infusing into the spinal fluid
- Clearly label the epidural catheter after placement
- Evaluate the effects of the drug on patient's alertness
- Site care must be done carefully to avoid dislodgement of catheter

**Advantages**

- Permits control or alleviation of severe pain without sedative effects
- Permits delivery of smaller doses of narcotic to achieve desired level of analgesia
- Allows for continuous infusion if needed



**Disadvantages**

- Nurses lack understanding of pharmacologic agents
- Only preservative-free narcotics can be used
- Complications such as paresthesia, urinary retention, respiratory depression, and pruritus can occur
- Catheter-related risks (dislodgement, infection)

**Monitoring Epidural Medication Administration**

- Mental status
- Respiratory rate
- Indications of numbness in the lower extremities
- Signs of infection
- Bowel function
- Bladder function
- Integrity of the epidural system
- Narcotic dose
- Patient's pain rating
- Epidural site observation and care
- Observe for ascending loss of sensation

**Intrathecal Medication Administration****Key Points**

- Intrathecal space lies between the ligamentum flavum and the dura mater
- Requires 10 times less medication than the epidural route
- Associated with greater risk for infection
- Intrathecal narcotics given as single injection
- Intrathecal infusions require implanted infusion pump

**Advantages**

- Useful for delivery of certain antineoplastic agents, antibiotics, analgesics, and anesthetic agents
- Effective alternative to oral or parenteral therapy for abatement of pain
- Allows for low doses of drug

**Disadvantages**

- Possible life-threatening side effects
- Potential for spinal fluid leak
- Potential for infection

*Refer to Chapter 11 in Manual of IV Therapeutics, 4th ed., for more information on medication delivery routes.*

**Intraperitoneal (IP) Medication Administration****Key Points**

- Tenckhoff catheter used or implanted port
- Instills high concentration of drugs directly into body cavity
- Used most frequently to deliver antineoplastic agents
- The peritoneal cavity acts as reservoir for drug
- Obtain baseline weight and measure abdominal girth
- Assess for complications associated with IP therapy:
  - Pain
  - Subcutaneous leakage
  - Hematoma or bleeding (rare)
  - Local infection
  - Colon perforation
- Flush catheter or port with sterile saline after use; if using port, follow with heparinized saline

**Advantages**

- When not in use, IP device is invisible
- No catheter site care
- Cytotoxic drugs are administered directly into tumor area

**Disadvantages**

- Can be difficult to locate and access the port
- Catheter infection can occur
- Buildup of fibrin sheath can occur on the distal catheter tip
- Abdominal adhesions can cause spaces in the cavity, preventing the flow of the infusion

*See Chapter 14 in Manual of IV Therapeutics, 4th ed., for more information on administration of medications via IP routes*

**Notes**

**Notes**

**Contents: TOOLS**

Common Laboratory Values	152
General Chemistry	153
Hematology (ABC, CBC, Blood Counts)	154
Coagulation	155
Normal Blood Gases	155
Common Abbreviations: Infusion Therapy	156
CDC (HICPAC) Isolation Precautions	156
Tier One: Standard Precautions	156
Tier Two: Transmission-Based Precautions	157
OSHA Guidelines	158
Resource List	160
Labs/Diagnostics	161
Symbols	164
Assessment Flowsheet	165

## Common Laboratory Values

### General Chemistry

Laboratory	Conventional	SI Units
Albumin	3.5–5.0 g/100 mL	35–50 g/L
Aldolase	1.3–8.2 U/L	22–137 nmol · s <sup>-1</sup> /L
Alkaline phosphatase	13–39 U/L, infants and adolescents up to 104 U/L	217–650 nmol · s <sup>-1</sup> /L, up to 1.26 μmol/L
Ammonia	12–55 μmol/L	12–55 μmol/L
Amylase	4–25 U/mL	4–25 arb. unit
Anion gap	8–16 mEq/L	8–16 mmol/L
AST, SGOT	Male: 8–46 U/L	0.14–0.78 μkat/L
	Female: 7–34 U/L	0.12–0.58 μkat/L
Bilirubin, direct	Up to 0.4 mg/100 mL	Up to 7 μmol/L
Bilirubin, total	Up to 1.0 mg/100 mL	Up to 17 μmol/L
BUN	8–25 mg/100 mL	2.9–8.9 mmol/L
Calcitonin	Male: 0–14 pg/mL	0–4.1 pmol/L
	Female: 0–28 pg/mL	0–8.2 pmol/L
Calcium (Ca <sup>+</sup> )	8.5–10.5 mg/100 mL	2.1–2.6 mmol/L
Carbon dioxide	24–30 mEq/L	24–30 mmol/L
Chloride (Cl <sup>-</sup> )	100–106 mEq/L	100–106 mmol/L
Cholesterol	<200 mg/dL	<5.18 mmol/L
Cortisol	a.m. 5–25 μg/100 mL	0.14–0.69 μmol/L
	p.m. <10 μg/100 mL	0–0.28 μmol/L
Creatine	Male: 0.2–0.5 mg/dL	15–40 μmol/L
	Female: 0.3–0.9 mg/dL	25–70 μmol/L
Creatine kinase (CK)	Male: 17–148 U/L	283–2467 nmol · s <sup>-1</sup> /L
	Female: 10–79 U/L	167–1317 nmol · s <sup>-1</sup> /L

(Continued)

## General Chemistry

Laboratory	Conventional	SI Units
Creatinine	0.6–1.5 mg/100 mL	53–133 $\mu\text{mol/L}$
Ferritin	10–410 ng/dL	
Folate	2.0–9.0 ng/mL	4.5–20.4 nmol/L
Glucose	70–110 mg/100 mL	3.9–5.6 mmol/L
Ionized calcium	4.26–5.25 mg/dL	1.1–1.3 mmol/L
Iron (Fe)	50–150 $\mu\text{g}/100\text{ mL}$	9.0–25.9 $\mu\text{mol/L}$
Iron-binding capacity (IBC)	250–410 $\mu\text{g}/100\text{ mL}$	44.8–73.4 $\mu\text{mol/L}$
Lactic acid	0.5–1.8 mEq/L	0.8–1.8 mmol/L
Lactic dehydrogenase (LDH)	45–90 U/L	750–1500 nmol $\text{s}^{-1}/\text{L}$
Lipase	2 U/mL or less	Up to 2 arb. unit
Magnesium ( $\text{Mg}^{++}$ )	1.5–2.0 mEq/L	0.8–1.3 mmol/L
Osmolality	280–296 mOsm/kg water	280–296 mmol/kg
Phosphorus	3.0–4.5 mg/100 mL	1.0–1.5 mmol/L
Potassium ( $\text{K}^+$ )	3.5–5.0 mEq/L	3.5–5.0 mmol/L
Prealbumin	18–32 mg/dL	
Protein, total	6.0–8.4 g/100 mL	80–84 g/L
PSA	0.0–4.0 ng/mL	
Pyruvate	0–0.11 mEq/L	0–0.11 mmol/L
Sodium ( $\text{Na}^+$ )	135–145 mEq/L	135–145 mmol/L
$\text{T}_3$	75–195 ng/100 mL	1.16–3.00 nmol/L
$\text{T}_4$ , free	Male: 0.75–2.0 ng/dL	
	Female: 0.75–2.0 ng/dL	
$\text{T}_4$ , total	4–12 $\mu\text{g}/100\text{ mL}$	52–154 nmol/L
Thyroglobulin	3–42 $\mu\text{mL}$	3–42 $\mu\text{g/L}$
Triglycerides	40–150 mg/100 mL	0.4–1.5 g/L
TSH	0.5–5.0 $\mu\text{U}/\text{mL}$	0.5–5.0 arb. unit
Urea nitrogen	8–25 mg/100 mL	2.9–8.9 mmol/L
Uric acid	3.0–7.0 mg/100 mL	0.18–0.42 mmol/L

<b>Hematology (ABC, CBC, Blood Counts)</b>		
Blood volume	8.5–9.0% of body weight in kg	80–85 mL/kg
Red blood cell (RBC)	Male: 4.6–6.2 million/mm <sup>3</sup>	4.6–6.2 × 10 <sup>12</sup> /L
	Female: 4.2–5.9 million/mm <sup>3</sup>	4.2–5.9 × 10 <sup>12</sup> /L
Hemoglobin (Hgb)	Male: 13–18 g/100 mL	8.1–11.2 mmol/L
	Female: 12–16 g/100 mL	7.4–9.9 mmol/L
Hematocrit (Hct)	Male: 45–52%	0.45–0.52
	Female: 37–48%	0.37–0.48
Leukocytes (WBC)	4.300–10.800/mm <sup>3</sup>	4.3–10.8 × 10 <sup>9</sup> /L
■ Bands	0–5%	0.03–0.08
■ Basophils	0–1%	0–0.01
■ Eosinophils	1–4%	0.01–0.04
■ Lymphocytes	25–40%	0.25–0.40
● B Lymphocytes	10–20%	0.10–0.20
● T Lymphocytes	60–80%	0.60–0.80
■ Monocytes	2–8%	0.02–0.08
■ Neutrophils	54–75%	0.54–0.75
Platelets	150,000–350,000/mm <sup>3</sup>	150–350 × 10 <sup>9</sup> /L
Erythrocyte sedimentation rate (ESR)	Male: 1–13 mm/h Female: 1–20 mm/h	1–13 mm/h 1–20 mm/h



## Coagulation

Laboratory	Conventional	SI Units
ACT	90–130 s	
PTT (activated)	21–35 s	21–35 s
Bleeding time	3–7 min	3–7 min
Fibrinogen	160–450 mg/dL	1.6–4.5 g/L
INR (target therapeutic)	2–3	2–3
Plasminogen	62–130%	0.62–1.30
Platelets	150,000–300,000/mm <sup>3</sup>	×10 <sup>6</sup> /L
PT (prothrombin time)	10–12 s	10–12 s
PTT (partial thromboplastin time)	30–45 s	30–45 s
Thrombin time	11–15 s	11–15 s

## Normal Blood Gases

Laboratory	Conventional	SI Units
pH	7.35–7.45	36–45 μmol/L
PO <sub>2</sub>	75–100 mm Hg	10.0–13.3 kPa
PCO <sub>2</sub>	35–45 mm Hg	4.7–6.0 kPa
HCO <sub>3</sub>	22–26 mmol/L	22–26 mmol/L
Base excess	(–2)–(+2) mEq/L	(–2)–(+2) mmol/L
CO <sub>2</sub>	19–24 mEq/L	19–24 mmol/L
SaO <sub>2</sub>	96–100%	0.96–1.00

## Common Abbreviations: Infusion Therapy

AGC	= absolute granulocyte count
BCAA	= branched-chain amino acids
BSA	= body surface area
BSC	= biologic safety cabinet
CDC	= Centers for Disease Control and Prevention
CPDA	= citrate-phosphate-dextrose-adeninine
C-TPN	= cyclic total parenteral nutrition
CVC	= central venous catheter
CVTC	= central venous tunneled catheter
ECF	= extracellular fluid
EID	= electronic infusion device
HD	= hazardous drugs
HLA	= human leukocyte antigen
HPN	= home parenteral nutrition
ICF	= intracellular fluid
IP	= intraperitoneal
OSHA	= Occupational, Safety, and Health Administration
PPN	= peripheral parenteral nutrition
PICC	= peripherally inserted central catheter
PPE	= personal protective equipment
PRN	= ( <i>pro re nata</i> ) = used to describe devices for intermittent transfusions
PSI	= pounds per square inch
TLC	= total lymphocyte count
TNA	= total nutrient admixture
TPN	= total parenteral nutrition
VAD	= vascular access device

## CDC (HICPAC) Isolation Precautions

### Tier One: Standard Precautions

#### Hand Hygiene

- Guidelines for hand washing and use of alcohol based

### Gloves

- Guidelines for use of gloves when touching blood, body fluids, secretions, excretions, and contaminated objects

### Mask—eye and face protection

- Wear a mask and eye protection to protect mucous membranes of eyes, nose, and mouth during procedure and patient-care activities that generate splashes or sprays

### Gown

- Wear gown to protect skin and prevent soiling of clothing during procedures and patient-care activities that are likely to generate splashes or sprays

### Patient Care Equipment

- Handle used patient-care equipment in a manner that prevents skin and mucous membrane exposures

### Linen

- Handle, transport, and process used linen soiled with blood, body fluids to prevent exposure and contamination of clothing

### Occupational health and bloodborne pathogens

- Guidelines for use of sharps, mouthpieces, resuscitation bags, and other ventilation devices

## Tier Two: Transmission-Based Precautions

1. Airborne precautions—Patients known or suspected to be infected with organism transmitted by airborne droplet nuclei smaller than 5 microns (e.g., varicella, TB)
  - Private room
  - Monitor negative air pressure (6–12 air changes per hour)
  - Room door closed and patient in room
  - Wear respiratory protection (N95 respirator)
  - Limit transportation
2. Droplet precautions—Use for known or suspected patients who have illnesses transmitted by particle droplets larger than 5 microns (e.g., mycoplasma pneumonia)

- Private room
  - If private room not available, place patient with a spatial separation of 3 ft or more
  - Door may remain open
  - Wear mask as in standard precautions when working within 3 ft of patient
  - Limit transportation; mask patient
3. Contact precautions—Use for known illnesses transmitted by direct contact with client (e.g., GI illnesses; respiratory, skin, or wound colonization with multi-drug-resistant bacteria, e.g., *Clostridium difficile*)
- Private room
  - Wear gloves and gown
  - Change gloves frequently
  - Good hand hygiene
  - Limit transportation
  - Dedicated equipment

## OSHA Guidelines

### Controlling Occupational Exposure to Hazardous Drugs (HDs)

1. Environmental Protection
  - Risk: aerosols, dermal absorption, and ingestion
  - HD prep-restricted-centralized area
  - Signs restricting access: posted
  - Smoking, drinking, applying cosmetics, chewing gum, and eating restricted
  - Biologic Safety Cabinet (BSC) use
  - Emergency procedures for spill and skin or eye contact available to workers
2. Personal Protective Equipment (PPE)
  - PPE must be donned before work started
  - Gloves: Use thicker, longer latex gloves that cover gown cuff
  - Gloves with no powder
  - Double-gloving recommended

- Change hourly or if torn
  - Gowns made of lint-free, low-permeability fabric; long sleeves, elastic cuffs
  - NIOSH-approved respirator worn when a BSC is not available
  - Use respirator with full face piece
  - Eyewash facilities should be available
  - Label all syringe and IV bags containing HDs
3. Drug Administration
- Wash hands prior to gloving
  - Use Luer-lock fittings
  - A plastic-backed absorbent pad should be placed under tubing during administration
  - Sterile gauze should be placed around push sites
  - Prime and air-purging should be done under BSC
  - Use sterile gauze to wipe clean any drug contamination
  - Dispose of administration set intact
  - Protective goggles should be cleaned with detergent and rinsed
4. Waste Disposal
- Thick leak-proof bags should be colored differently from other hospital trash
  - Use sharps container
  - Waste should be clearly labeled "HD Waste Only"
  - Incidental spills and breakages should be cleaned up by properly protected person
5. Storage and Transport
- Storage areas: limit access to authorized personnel
  - Do not use for storing other drugs
  - Warning labels should be applied to all HD containers
  - HDs should be securely capped or sealed
  - Personnel transporting HDs should be trained in spill procedures
6. Medical Surveillance
- Preplacement medical examination prior to working with HDs
  - Update every 2–3 years
  - Postexposure evaluation tailored to type of exposure

## 7. Hazardous Communication

- Employers must develop, implement, and maintain written hazard communications for employees handling HDs.

## 8. Training and Information Dissemination

- Employees must be informed of the requirements of the hazard communication standard and those for any operation or procedure in their work area where drugs that present a hazard are present.

## Resource List

American Association of Critical Care Nurses (AACN)

[www.aacn.org](http://www.aacn.org)

American Pain Society [www.ampainsoc.org](http://www.ampainsoc.org)

American Society for Parenteral and Enteral Nutrition

[www.aspen.org](http://www.aspen.org)

Association for Professionals in Infection Control and Epidemiology [www.apic.org](http://www.apic.org)

Centers for Disease Control and Prevention [www.cdc.gov](http://www.cdc.gov)

Epinet [www.med.virginia.edu](http://www.med.virginia.edu)

Infusion Nurses Society (INS) [www.ins1.org](http://www.ins1.org)

Joint Commission on Accreditation of Health Care Organizations

[www.jcaho.org/standard](http://www.jcaho.org/standard)

Latex Allergy [www.latexallergyn.com](http://www.latexallergyn.com)

Medical Glove Guidance Manual [www.fda.gov/cdrh/manual/glovenaul.pdf](http://www.fda.gov/cdrh/manual/glovenaul.pdf)

National Association of Vascular Access Networks

[www.navannet.org](http://www.navannet.org)

Oncology Nursing Society [www.ons.org](http://www.ons.org)

Occupational Safety and Health Administration [www.osha.gov](http://www.osha.gov)

## Labs/Diagnostics

Time

## General Chemistry

↓	Na <sup>+</sup>	Cl <sup>-</sup>	K <sup>+</sup>	Ca <sup>+</sup>	Mg <sup>++</sup>	Glu	BUN	Creat.			

## Hematology

## Cardiac Enzymes

Hct	Hgb	RBC	WBC	Platelets	Troponin -I	Troponin -T	CPK -MB	SGOT	LDH	Myoglobin

## Coagulation

## Blood Gases



ACT	PT	INR	PTT	thrombin-time	pH	PO <sub>2</sub>	PCO <sub>2</sub>	HCO <sub>3</sub>	BE	CO <sub>2</sub>	SaO <sub>2</sub>

<b>Intake</b>	<b>Amt in</b>	<b>Output</b>	<b>Amt out</b>
IVF		Urine	
IVPB		NG drainage/emesis	
Blood/Colloid			
Oral Intake		Liquid stool	
		Other	
Total in		Total out	





## Symbols

$1^{\circ}$	.....primary, 1st degree
$2^{\circ}$	.....secondary, 2nd degree
$3^{\circ}$	.....tertiary, 3rd degree
$\Delta$	.....change
$\emptyset$	.....no, none
$\Psi$	.....psychiatric
$<$	.....less than
$>$	.....greater than
$\mu$	.....micro
$\mu\text{g}$	.....microgram
$\approx$	.....approximately
$\#$	.....pound, number
"	.....second, inch
	.....increase
	.....decrease
$=$	.....equal to, the same
$\neq$	.....unequal, not equal
$\geq$	.....greater than or equal to
$\leq$	.....less than or equal to
$\sigma$	.....male
$\rho$	.....female
$^{\circ}$	.....hour, degree
@	.....at
$\alpha$	.....alpha
$\beta$	.....beta
$R_x$	.....prescription, to treat, medications

## Assessment Flowsheet

Patient

DX/ S/P

Time



Vital Signs

Notes

BP

HR

RR

O<sub>2</sub> sats

Temp

on

on

on

on

on

on

on

on

**Notes**

## Index

Note: Page numbers followed by f refer to illustrations.

## A

- ABO blood grouping, 106
  - type compatibility within, 106. *See also* Blood transfusion.
- Access devices, central vascular. *See also* Central venous catheter(s).
  - blood sampling from, 89–90
  - complications associated with, 94–99
  - flushing of, 54
- Acid-base scale, 24f
  - imbalances on, 25, 26
- Acidifying solutions, 28
- Acidosis, 25, 26
- Acute acid-base imbalances, 26
- Acute hemolytic reaction, to transfusion, 117
- Adrenergic agents, extravasation of, 65
  - antidotes for, 65
- Air, in pleural space, in patient with central vascular access device, 94
- Air embolism
  - in patient receiving nutritional support, 136
  - in patient with central vascular access device, 96
  - in recipient of peripheral IV therapy, 62
- Albumin
  - intravenous, 28, 31, 112
  - normal serum levels of, 152
- Alkalinizing solutions, 28
  - extravasation of, 66
  - antidotes for, 66
- Alkalosis, 25, 26
- Alkylating agents, extravasation of, 67
  - antidotes for, 67
- Allergic reaction, to transfusion, 119
- “All-in-one” solutions (“3-in-1” solutions, total nutrient admixtures), 133–134
- Amino acid solutions, for total parenteral nutrition, 128
- Analgesics
  - intradermal, 56
  - transdermal, 55
- Anaphylactic reaction, to transfusion, 119
- Anesthetics, local, 54
  - intradermal, 56
  - transdermal, 55
- Antecubital veins, 38, 76f
  - catheters for, gauge of, 38
- Antibiotic antineoplastic agents, extravasation of, 70
  - antidotes for, 70
- Antidotes, for extravasation of intravenous fluids, 65–72

- Antihypertensive agents,  
extravasation of, 68  
antidote for, 68
- Antineoplastic agents, extrava-  
sation of, 69, 70  
antidotes for, 69, 70
- Arterial blood gases, normal,  
155
- Assessment flowsheet, 165
- Axillary vein, length and diam-  
eter of, 76
- B**
- Basilic vein, 36f, 37f, 76f  
blood flow in, 35  
catheter for, gauge of, 38  
length and diameter of, 76
- Blood, in pleural space, in  
patient with central vascular  
access device, 94
- Blood components, transfu-  
sion of, 110–113. *See also*  
Blood transfusion.
- Blood counts, 154
- Blood flow, in veins, 35
- Blood gases, normal, 155
- Blood grouping, ABO, 106  
type compatibility within,  
106. *See also* Blood trans-  
fusion.
- Blood preservatives, 107
- Blood sampling  
with central vascular access  
device, 89–90  
with peripherally inserted  
central catheter, 85
- Blood transfusion, 106–123  
administration of, 114–115  
collection/donation for,  
107–108  
components used in, 110–113  
donor-recipient compatibility  
in, 106  
equipment for, 85, 108–109  
risks associated with,  
116–123  
testing preceding, 106–107
- Blood warmers, 109
- Body fluid(s)  
osmolarity of, 12  
percentage contribution of,  
to weight, 12
- Body surface area, calculation  
of, 2, 3
- Brachial plexus injury, in  
patient with central vascular  
access device, 95
- Brachiocephalic vein, right,  
length and diameter of, 76
- C**
- Calcium  
normal serum levels of, 21,  
152, 153  
variance from normal serum  
levels of, 21  
signs of, 21, 22f
- Calcium deficit, 21  
signs of, 21, 22f
- Calcium excess, 21
- Cancer chemotherapy, extrava-  
sation of agents used in, 69,  
70  
antidotes for, 69, 70
- Catheter(s), 78–79, 101–103  
blood transfusion, 108  
central. *See* Central venous  
catheter(s).  
common venous sites for,  
36f, 37f, 37–38, 76f

- damage to, in patient with central vascular access device, 98
- dislodgment of, in patient with central vascular access device, 96
- flushing of, 53, 81–82, 87–88, 101, 102, 103
- forearm vein, gauge of, 37–38
- implanted port. *See under* Central venous catheter(s).
- insertion of, in venipuncture, 44, 44f, 45, 45f
- malposition of
  - in patient receiving nutritional support, 136
  - in patient with central vascular access device, 96
- migration of, in patient with central vascular access device, 96
- occlusion of, 100
  - in patient with central vascular access device, 97
- percutaneous central, 78, 79, 101
- peripherally inserted. *See under* Central venous catheter(s).
- stabilizing of, in venipuncture, 47, 47f
- triple-lumen, injection ports of, 77, 77f
- tunneled. *See under* Central venous catheter(s).
- Catheter embolism, as complication of peripheral IV therapy, 62
- Centers for Disease Control and Prevention, isolation precautions issued by, 156–158
- Central vascular access devices. *See also* Central venous catheter(s).
  - blood sampling from, 89–90
  - complications associated with, 94–99
  - flushing of, 54
- Central venous catheter(s), 78–79
  - care of, 101–103
  - flushing of, 53, 81–82, 87–88, 101, 102, 103
  - implanted port, 79, 90, 91f
    - approach to accessing, 92
    - approach to deaccessing, 93
  - care of, 103
  - flushing of, 53, 103
  - occlusion of, 100
  - percutaneous, 78, 101
  - peripherally inserted, 78, 80, 80f
    - blood administration with, 85
    - blood sampling with, 85
    - care of, 102
    - discontinuation of, 83
    - flushing of, 53, 81–82, 102
    - “stuck,” removal of, 84

- Central venous catheter(s)  
(*continued*)  
tunneled, 78, 86f, 87  
flushing of, 53, 87–88
- Cephalic vein, 36f, 37f, 76f  
blood flow in, 35  
catheter for, gauge of, 38  
length and diameter of, 76
- Chemistry reference values,  
152–153
- Chemotherapy, extravasation  
of agents used in, 69, 70  
antidotes for, 69, 70
- Chevron method, of stabilizing  
catheter, in venipuncture, 47,  
47f
- Children, intravenous solutions  
for, 3–4
- Chloride  
normal serum levels of, 24,  
152  
variance from normal serum  
levels of, 24
- Chloride deficit, 24
- Chvostek's sign, 22f
- Chylothorax, in patient with  
central vascular access  
device, 94
- Circulatory overload, in trans-  
fusion recipient, 120
- Citrate toxicity, in transfusion  
recipient, 122
- Coagulation imbalances, in  
transfusion recipient, 121
- Coagulation studies, normal  
results of, 155
- Cryoprecipitate, 111
- Cyclic total parenteral nutri-  
tion, 134
- Cytomegalovirus infection,  
transfusion-transmitted,  
123
- D**
- Delayed hemolytic reaction, to  
transfusion, 117
- Dermis, 34f, 34–35
- Dextran, 28, 30
- Dextrose solutions, 27, 29  
for total parenteral nutrition,  
128
- Digital veins, 36f  
catheters for, gauge of, 37
- Diluents, for drugs, quantifica-  
tion of needed amounts of,  
8–9
- Direct IV push, administering  
of medications via, 56–57,  
143
- Dressing, application of, at site  
of venipuncture, 48, 50f
- Drinking water, osmolality of,  
153
- Drug delivery/drug administra-  
tion, 142–148  
determination of diluent  
amounts needed in, 8–9  
direct IV push in, 56–57, 143  
epidural route of, 146–147  
intraosseous route of,  
145–146  
intraperitoneal route of, 148  
intrathecal route of, 147–148  
piggyback method of, 51, 55,  
55f, 142, 142f  
quantification of amount for  
syringe in, 2, 5  
subcutaneous route of, 145



- volume control chamber in, 143–144, 144f
- Drug hazard exposure, occupational, control of, 158–159
- E**
- Electrocardiographic findings  
in hyperkalemia, 20f  
in hypokalemia, 20f
- Electrolyte imbalances, 14–16, 20–24
- Electrolyte solutions, extravasation of, 71  
antidote for, 71
- Embolism. *See also*  
Thrombosis.  
in patient receiving nutritional support, 136  
in patient with central vascular access device, 96  
in recipient of peripheral IV therapy, 62
- Enteral nutrition, algorithm for selection of, 130f
- Epidermis, 34, 34f
- Epidural administration, of medications, 146–147  
monitoring of, 147
- Essential fatty acids, deficiency of, in patient receiving nutritional support, 139
- Extravasation (infiltration), of intravenous solutions, 60, 63, 64–72  
antidotes for, 65–72
- F**
- Fatty acids, deficiency of, in patient receiving nutritional support, 139
- Febrile reaction, to transfusion, 118
- Fluid overload, in recipient of peripheral IV therapy, 61
- Fluid shifts, tonicity and, 13
- Fluid volume deficit, 14
- Fluid volume excess, 14
- Flushing  
of catheters, 53, 81–82, 87–88, 101, 102, 103  
of central vascular access devices, 54  
of intermittent infusion devices, 52
- Forearm, veins of, 36f, 37f  
catheters for, gauge of, 37–38
- Formula calculation, of IV infusion rates, 2, 5, 7  
for pediatric patients, 3–4
- Fresh frozen plasma, 110
- G**
- Glucose  
normal serum levels of, 153  
variance from normal serum levels of, in patient receiving nutritional support, 137
- Graft-vs.-host disease, in transfusion recipient, 120
- H**
- H method, of stabilizing catheter, in venipuncture, 47, 47f

- Hand hygiene, preparatory to venipuncture, 39–40
- Hazardous drug exposure, occupational, control of, 158–159
- Hematology reference values, 154
- Hematoma, in recipient of peripheral IV therapy, 59
- Hemolytic reaction, to transfusion, 117
- Hemothorax, in patient with central vascular access device, 94
- Heparin flush, 53, 54
- Hepatic formulas, in parenteral nutrition, 135
- Hepatitis, transfusion-transmitted, 116, 123
- Hetastarch, 28
- Human immunodeficiency virus infection, transfusion-transmitted, 116, 123
- Hydrating solutions, 27, 30
- Hypercalcemia, 21
- Hyperglycemia, in patient receiving nutritional support, 137
- Hyperkalemia, 16  
electrocardiographic findings associated with, 20f
- Hypermagnesemia, 23
- Hypernatremia, 15
- Hypertonic solutions, extravasation of, 72  
antidote for, 72
- Hypertonicity, and fluid shifts, 13
- Hypervolemia, 14
- Hypocalcemia, 21  
signs of, 21, 22f
- Hypochloremia, 24
- Hypoglycemia, in patient receiving nutritional support, 137
- Hypokalemia, 16  
electrocardiographic findings associated with, 20f  
in patient receiving nutritional support, 137
- Hypomagnesemia, 23
- Hyponatremia, 15
- Hypothermia, in transfusion recipient, 122
- Hypotonicity, and fluid shifts, 13
- Hypovolemia, 14
- I**
- Immune serum globulin, 113
- Implanted port catheter, 79, 90, 91f  
approach to accessing, 92  
approach to deaccessing, 93  
care of, 103  
flushing of, 53, 103
- Infection  
in patient receiving nutritional support, 138  
in patient with central vascular access device, 98  
in person exposed to pathogens, prevention of, 156–158  
in recipient of peripheral IV therapy, 60, 61  
in transfusion recipient, 116, 123

- Infiltration (extravasation), of intravenous fluids, 60, 63, 64–72  
antidotes for, 65–72
- Infusion devices, intermittent, 52  
flushing of, 52
- Injection ports, of triple-lumen catheter, 77, 77f
- Intake/output record forms, 162–163
- Intermittent infusion devices, 52  
flushing of, 52
- Intradermal analgesic, 56
- Intraosseous administration, of medications, 145–146
- Intraperitoneal administration, of medications, 148
- Intrathecal administration, of medications, 147–148
- Intravenous solutions, 27–31  
calculating rates of infusion of, 2, 7  
in children, 3–4  
using universal formula, 5  
complications associated with, 59–72  
discontinuation of, 57–58  
drop rates of, 6  
extravasation (infiltration) of, 60, 63, 64–72  
antidotes for, 65–72  
pediatric, 3–4
- Irrigation. *See* Flushing.
- Isolation precautions, 156–158
- Isotonicity, and fluid shifts, 13
- J**
- Job-related hazardous drug exposure, control of, 158–159
- K**
- Kwashiorkor, 127
- L**
- Laboratory tests  
normal results of, 152–155  
recording of results of, sample form for, 161
- Lactated Ringer's solution, 27, 30
- Lipid emulsions, for total parenteral nutrition, 129
- Local anesthetics, 54  
intradermal, 56  
transdermal, 55
- M**
- Magnesium  
normal serum levels of, 23, 153  
variance from normal serum levels of, 23
- Magnesium deficit, 23
- Magnesium excess, 23
- Malnutrition, 127
- Mannitol, 28, 31
- Marasmus, 127
- Median antecubital veins, 38  
catheters for, gauge of, 38
- Medications. *See* Drug entries.
- Metabolic acidosis, 25, 26
- Metabolic alkalosis, 25, 26
- Metacarpal veins, 36f  
catheters for, gauge of, 38

Mixed malnutrition, 127  
 Multiple electrolyte solutions,  
 27, 30

## N

Needle(s), venipuncture, 43  
 insertion of, 44, 44f  
 Nonhemolytic transfusion  
 reaction, 118  
 Nutritional assessment,  
 126–127  
 Nutritional support, 131  
 complications associated  
 with, 136–139  
 enteral, algorithm for selec-  
 tion of, 130f  
 parenteral. *See* Parenteral  
 nutrition.

## O

Occupational hazardous drug  
 exposure, control of,  
 158–159  
 Osmolality, of drinking water,  
 153  
 Osmolarity  
 of fluids, 12  
 of intravenous solutions,  
 29–31

## P

Parenteral nutrition, 132, 133,  
 134  
 algorithm for selection of,  
 130f  
 peripheral, 132  
 specialized formulas used in,  
 135  
 total, 132–133

amino acid solutions for,  
 128  
 cyclic, 134  
 dextrose solutions for, 128  
 lipid emulsions for, 129  
 protein solutions for, 128  
 Pathogen exposure, prevention  
 of, 156–158  
 Pediatric patients, intravenous  
 solutions for, 3–4  
 Penicillins, extravasation of, 71  
 antidote for, 71  
 Percutaneous central venous  
 catheter, 78, 79, 101  
 Peripheral intravenous therapy,  
 solutions used in. *See*  
 Intravenous solutions.  
 Peripheral parenteral nutrition,  
 132  
 Peripheral vasculature, 36f, 37f,  
 37–38. *See also* Vein(s).  
 Peripherally inserted central  
 catheter, 78, 80, 80f  
 blood administration with,  
 85  
 blood sampling with, 85  
 care of, 102  
 discontinuation of, 83  
 flushing of, 53, 81–82, 102  
 “stuck,” removal of, 84  
 Phlebitis, 63  
 in recipient of peripheral IV  
 therapy, 59, 64  
 Piggyback method, of adminis-  
 tering medications, 51, 55,  
 55f, 142, 142f  
 Plasma expanders, 30  
 Plasma, fresh frozen, 110  
 Plasma protein fraction, 113

- Platelet count, normal, 154, 155
- Platelet transfusion, 110
- Pleural space, air- or fluid-filled, in patient with central vascular access device, 94
- Pneumothorax, in patient with central vascular access device, 94
- Port(s)  
 implanted, 79, 90, 91f  
   approach to accessing, 92  
   approach to deaccessing, 93  
   care of, 103  
   flushing of, 53, 103  
   injection, of triple-lumen catheter, 77, 77f
- Potassium  
 intravenous administration of. *See* Potassium chloride.  
 normal serum levels of, 16, 153  
 variance from normal serum levels of, 16  
   electrocardiographic findings associated with, 20f  
   in patient receiving nutritional support, 137
- Potassium chloride  
 administration of, 17  
 medications compatible with, 18–19  
 medications incompatible with, 19
- Potassium deficit, 16  
 electrocardiographic findings associated with, 20f  
 in patient receiving nutritional support, 137
- Potassium excess, 16  
 electrocardiographic findings associated with, 20f
- Potassium toxicity, in transfusion recipient, 121
- Protein solutions, for total parenteral nutrition, 128
- R**
- Rebound hypoglycemia, in patient receiving nutritional support, 137
- Red blood cell count, normal, 154
- Red blood cell transfusion, 110.  
*See also* Blood transfusion.  
 type compatibility and, 106
- Refeeding syndrome, in patient receiving nutritional support, 138
- Renal formulas, in parenteral nutrition, 135
- Respiratory acidosis, 25, 26
- Respiratory alkalosis, 25, 26
- Right brachiocephalic vein, length and diameter of, 76
- Ringer's solution, lactated, 27, 30
- S**
- Saline solutions, 27, 29  
 flushing with, 52, 54
- Sepsis/septicemia. *See also* Infection.  
 in patient receiving nutritional support, 138

- Sepsis/septicemia (*continued*)  
 in recipient of peripheral IV therapy, 61
- Skin, 34f, 34–35
- Sodium  
 normal serum levels of, 15, 153  
 variance from normal serum levels of, 15
- Sodium chloride solutions, 27, 29  
 flushing with, 52, 54
- Sodium deficit, 15
- Sodium excess, 15
- Spasm, venous, in recipient of peripheral IV therapy, 60
- Speed shock, in recipient of peripheral IV therapy, 62
- Stress formulas, in parenteral nutrition, 135
- Subclavian vein, 76f  
 blood flow in, 35  
 length and diameter of, 76
- Subcutaneous administration, of medications, 145
- Superior vena cava, 76  
 blood flow in, 35  
 length and diameter of, 76
- Superior vena cava syndrome, in patient with central vascular access device, 99
- Surface area of body, calculation of, 2, 3
- Symbols, 164
- Syringe, amount of drug to be dispensed via, quantification of, 2, 5
- T**
- “3-in-1” solutions (“all-in-one” solutions, total nutrient admixtures), 133–134
- Thrombosis. *See also* Embolism.  
 in patient receiving nutritional support, 136  
 in recipient of peripheral IV therapy, 59
- Total nutrient admixtures (“all-in-one” solutions, “3-in-1” solutions), 133–134
- Total parenteral nutrition, 132–133  
 amino acid solutions for, 128  
 cyclic, 134  
 dextrose solutions for, 128  
 lipid emulsions for, 129  
 protein solutions for, 128
- Transdermal analgesic, 55
- Transfusion, 106–123  
 administration of, 114–115  
 blood collection for, 107–108  
 blood components used in, 110–113  
 blood testing preceding, 106–107  
 donor-recipient compatibility in, 106  
 equipment for, 85, 108–109  
 risks associated with, 116–123
- Triple-lumen catheter, injection ports of, 77, 77f
- Trousseau’s sign, 22f
- Tunics of vein(s), 35f, 36

- Tunneled central venous catheter, 78, 86f, 87  
flushing of, 53, 87–88
- Twiddler's syndrome, in patient with central vascular access device, 96
- U**
- U method, of stabilizing catheter, in venipuncture, 47, 47f
- Universal formula  
for calculating drug administration, 5  
for quantifying IV infusion rates, 5
- V**
- Vascular access devices, central. *See also* Venous catheter(s), central.  
blood sampling from, 89–90  
complications associated with, 94–99  
flushing of, 54
- Vein(s), 35–36  
blood flow in, 35  
commonly catheterized, 36f, 37f, 37–38, 76f  
length and diameter of, 76  
entry into. *See* Venipuncture.  
forearm, 36f, 37f  
catheters for, gauge of, 37–38  
inflammation of, 63  
in recipient of peripheral IV therapy, 59, 64  
spasm of, in recipient of peripheral IV therapy, 60  
thromboembolism in. *See* Embolism; Venous thrombosis.  
tunics of, 35f, 36
- Vena cava, superior, 76  
blood flow in, 35  
length and diameter of, 76  
occlusion of, in patient with central vascular access device, 99
- Venipuncture, 39–49  
dressing applied at site of, 48, 50f  
hand hygiene preparatory to, 39–40  
insertion of catheter in, 44, 44f, 45, 45f  
needle(s) used in, 43  
insertion of, 44, 44f  
selection of site for, 42  
stabilizing of catheter in, 47, 47f
- Venous catheter(s), central, 78–79  
care of, 101–103  
flushing of, 53, 81–82, 87–88, 101, 102, 103  
implanted port, 79, 90, 91f  
approach to accessing, 92  
approach to deaccessing, 93  
care of, 103  
flushing of, 53, 103  
occlusion of, 100  
percutaneous, 78, 79, 101  
peripherally inserted, 78, 80, 80f  
blood administration with, 85

- Venous catheter(s) (*continued*)  
  blood sampling with, 85  
  care of, 102  
  discontinuation of, 83  
  flushing of, 53, 81–82, 102  
  “stuck,” removal of, 84  
  tunneled, 78, 86f, 87  
    flushing of, 53, 87–88
- Venous system. *See* Vein(s).
- Venous thrombosis. *See also*  
  Embolism.  
  in patient receiving nutri-  
    tional support, 136  
  in recipient of peripheral IV  
    therapy, 59
- Viral infection, transfusion-  
  transmitted, 116, 123
- Volume control chamber,  
  medication delivery through,  
  143–144, 144f
- Volume deficit, 14
- Volume excess, 14
- W**
- Water, potable, osmolality of,  
  153
- Work-related hazardous drug  
  exposure, control of,  
  158–159
- X**
- X-ray study, of “stuck” periph-  
  erally inserted central  
  catheter, 84





**Notes**

## Notes

**Notes**

## Notes

**Notes**

